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ABSTRACT 
Genetic loci identified by single variant association tests account for only a small 
proportion of the heritability for most complex traits and diseases. Part of the unexplained 
heritability may be due to rare variants and their interactions with environmental factors. 
Different strategies have been taken to increase the power to detect genetic associations, 
such as increasing the sample size by including related participants and meta-analyzing 
multiple studies. Longitudinal data or repeated measurements are often available in 
prospective cohort studies. For complex diseases, multiple traits are usually collected to 
characterize affected individuals. Many of the existing statistical methods can only be 
applied to the scenarios when each participant has one measurement of a single trait. To 
take full advantage of the data and further improve power, multiple measurements per 
individual may be included in the analysis when available. In this dissertation we develop 
statistical methods for rare variant association testing and gene by environment 
 vi 
 
interaction analysis, and discuss gene-based meta-analysis for studies with different 
designs. First, we propose the generalized Sequence Kernel Association Test (genSKAT) 
to deal with rare variants, familial correlation, and repeated measurements or multiple 
traits. This is an extension of the original SKAT and family-based SKAT that accounts 
for correlation between multiple measurements within each individual. In the second part 
of this dissertation, we discuss methods to test for the presence of gene-environment 
interaction effects in the genSKAT framework. Finally, we evaluate genSKAT meta-
analysis methods to combine different types of studies: samples of unrelated individuals 
with one observation per person or with multiple observations per person, and family 
samples with one observation per person or with multiple observations per person. 
Combining all these projects together, we contribute methodologies to detect rare variant 
associations by taking advantage of additional information, improve the chance to detect 
novel rare variant associations, and help in understanding the role that genetic factors 
play in various diseases and traits. 
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Chapter 1 Introduction 
1.1 Genetics Association Studies 
In genetics association studies, we are interested in testing the effect of a specific allele 
on a given trait. Such association may be due to the functional effect of the genetic 
variant on the traits, or the genetic variant is in linkage disequilibrium with a functional 
genetic variant. Depending on whether the trait is qualitative or quantitative, different 
association tests are used. For qualitative traits, Chi-square tests or Fishers exact tests are 
commonly applied for case-control studies, and logistic regression is usually applied 
when adjustment for covariates is needed. For quantitative traits, linear regression is 
usually performed.  
 
With the development of technology and the decreasing cost of genotyping, genome-wide 
association studies (GWAS) have been widely used to detect the association between 
genetic variants and complex diseases or traits. GWAS evaluate association with single 
nucleotide polymorphisms (SNPs) across the genome, which are common genetic 
variants defined by minor allele frequency (MAF) no less than 1%. In GWAS, a single 
variant association test, like logistic regression or linear regression, is performed for each 
2 
 
 
common variant. The p-value threshold of significance is adjusted for multiple testing. 
Since the first successful study in 2005 [27], GWAS have identified thousands of SNPs 
related to multiple complex conditions including cardiovascular diseases, diabetes, and 
pulmonary diseases [1] [15] [19] [38] [47].  
 
However, the genetic loci identified by single variant association tests account for only a 
small proportion of the heritability for most complex traits and diseases. Several reasons 
may account for the low heritability. First, part of the unexplained heritability may be due 
to rare variants [14]. Some large sample size studies revealed that the majority of genetic 
variants are rare variants [49] [59]. Some rare variants may have medical or biological 
effects on human diseases [9] [16] [17] [26] [40] [52]. In recent years, rapid advances in 
sequencing technologies, such as next-generation sequencing (NGS), provide 
opportunities to assess the effect of rare variants. At the same time, many statistical 
models for rare variant association analysis have been proposed, including the burden 
tests [2] [20] [34] [41] [45] [46] [51] [63], variance component tests [8] [36] [48] [50] 
[62], and combined tests [11] [24] [33]. Second, a portion of the variation in a given trait 
or disease may also be due to environmental factors and their interactions with genetic 
variants [18] [21] [53]. Many statistical methods for detecting gene-environment (G-E) 
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interaction have been proposed [7] [25] [28] [29] [35] [42] [44] [60] [61]. Third, some 
previous studies had in the order of hundreds of individuals. The relatively small sample 
size limits the power to detect the association of rare variants or variants with small effect 
sizes with traits [43]. Meta-analyzing data from a number of studies are usually applied to 
overcome this issue [3] [23] [32] [58] [64].  
 
1.1.1 Rare Genetic Variants Analysis 
Single variant tests usually have lower power to detect association with rare variants 
compared to common variant tests [34]. Many statistical methods have been proposed to 
improve power to detect association with rare variants [2] [8] [11] [17] [22] [24] [33] 
[34] [36] [41] [45] [46] [48] [50] [51] [62] [63]. These approaches usually evaluate the 
association between a trait and mutiple rare variants in a gene or a region, instead of 
testing only one variant at a time. Power will be increased if multiple variants in the 
group are associated with the trait. 
 
A typical statistical model for rare variants association tests is 
𝝁(𝒚) = 𝑿𝜷 + 𝑮𝜸 + 𝝐, 
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where 𝝁() is a link function, 𝑿 is a design matrix including covariates, 𝑮 is a genotype 
matrix of rare variants,  𝜷 and 𝜸 are vectors of regression coefficients for 𝑿 and 
𝑮 respectively. The null hypothesis of interest is  
𝐻0: 𝜸 = 𝟎 
 
Burden tests [2] [34] [41] [45] [46] [63] collapse rare variants into a single genetic score 
by a weighted sum statistic. The association between this genetic score and the trait is 
tested. Burden tests are powerful when all variants have the same direction of effect. 
However, burden tests lose power substantially when most of the rare variants are null or 
rare variants have effects in opposite directions [4] [8] [33] [48]. To improve the power in 
the presence of null variants or bi-direction of effects, data-adaptive burden tests have 
been proposed. For the aSum test [20], negative weights are assigned to single nucleotide 
variants (SNVs) when the effect sizes are estimated to be negative. The variable-
threshold (VT) method [51] optimizes the minor allele frequency threshold to select rare 
variants. Adaptive burden tests are more robust and more powerful than the original 
burden tests in the presence of null, protective and harmful variants. But usually p-values 
cannot be estimated analytically and such tests may require permutations to evaluate 
significance. Therefore many adaptive tests are computationally intensive.  
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The score-based variance component test is another class of rare variants association 
tests [8] [48] [50] [62]. In these tests, a score test statistic for a group of rare variants is 
created, and the distribution of the test statistic is evaluated. Instead of combing rare 
variants like burden tests, variance component tests use aggregated score test statistics. 
Variance component tests are more powerful than burden tests in the presence of rare 
variants with different direction of effects [4] [8] [33] [48] [50] [62], and are 
computationally efficient because permutation procedures are not required to evaluate 
statistical significance [10]. However variance component tests are less powerful than 
burden tests when most variants have the same direction of effects [4] [8] [33] [48] [50] 
[62]. The Sequence Kernel Association Test (SKAT), proposed by Wu et al. in 2011 
[62], is a commonly used variance component test. It has been shown to be a powerful 
method in various scenarios. In 2013, Chen et al. extended the original SKAT to family-
based SKAT (famSKAT) [8] for quantitative traits to account for familial correlation 
among related individuals. 
 
Because of the pros and cons mentioned above, burden tests and variance component 
tests suit different scenarios. Some methods have been proposed to combine burden and 
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variance component test statistics. For instance, Lee et al. have proposed SKAT-O [33], 
an adaptive procedure to create a linear combination of SKAT and burden test statistics. 
Jiang et al. developed MONSTER [24], an extension of SKAT-O to accommodate 
familial correlation. The combined approaches are robust because the true association 
pattern between genetic variants and a given trait is usually unknown.  
 
1.1.2 Gene-Environment Interaction 
Both genetics and environmental exposures have effects on many phenotypes. There may 
also be some gene-environment interaction effects. For instance, individuals with specific 
genotypes may have different responses to lifestyle, treatment, drug dosages, or 
exposures. More genetic association studies are taking the interaction between genes and 
environment into consideration in recent years. There are two main purposes of including 
G-E interaction terms in a statistical model. First, the power to detect genetic effects may 
be increased when the gene-environment interaction exists and is correctly included in 
the model. Second, detecting a significant interaction effect itself may help in 
understanding the disease mechanism.  
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Usually, the statistical model for gene-environment interaction tests is 
𝝁(𝒚) = 𝑿𝜷 + 𝑮𝜸 + 𝑬𝑮𝜼 + 𝝐, 
where 𝝁() is a link function, 𝑿 is a design matrix including covariates, 𝑮 is a genotype 
matrix of rare variants, 𝑬 is a matrix for environment factors that are also included in 𝑿, 
and 𝜷, 𝜸, and 𝜼 are vectors of regression coefficients for covariates, genotype, and G-E 
interaction respectively.  
 
The null hypothesis to detect a genetic effect in the presence of G-E interaction is a joint 
test of   
𝐻0: 𝜸 = 𝜼 = 𝟎. 
The null hypothesis to detect a G-E interaction is  
𝐻0: 𝜼 = 𝟎. 
There are several methods to test interactions between common variants and environment 
[28] [29] [42] [44] [60]. Manning et al. proposed jointly estimating genetic main effects 
and G-E interation effects for meta-analysis [42]. Moreno-Macias et al. discussed G-E 
interaction tests for a single measurement per person, e.g. OLR and FBAT, and for 
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longitudinal measures, e.g. OLMM and two-step modeling approach [44]. These methods 
usually lack power if directly applied to test interactions between rare variants and 
environment. Some set-based association testing methods have been proposed to improve 
the power of detecting G-E interaction for rare variants [7] [25] [35] [61]. Among them, 
Chen et al. discussed an interaction test for rare variants under the SKAT framework [7].  
 
1.1.3 Meta-analysis 
The rare variants association studies require large sample sizes to be well powered, 
especially when the effect size is not large [31]. Because of the high cost of sequencing 
and privacy issues, it is usually difficult to recruit more participants within a study. 
However, there may be different studies with the same traits available, and power may be 
increased when combining studies. Meta-analysis is often used to analyze data across 
studies to increase power because it does not require access to the individual level data. 
 
One meta-analysis approach developed in the context of rare variants is based on 
combining test statistics instead of regression coefficients, because the regression 
coefficients may have very large variances due to the low allele frequency [32]. This 
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approach needs the minor allele frequency and score statistics for each rare variant, and 
the covariance matrix of the score statistics from each study. Test statistic based meta-
analysis approaches can accommodate results from burden tests, SKAT, and SKAT-O. 
 
1.2 Genetics Association Studies for Multiple Measurements 
Different strategies have been taken to increase the power to detect genetic associations, 
such as increasing the sample size by including additional study participants and meta-
analyzing multiple studies. Longitudinal data or repeated measurements are often 
available in prospective cohort studies. Oftentimes, association between genetic variants 
and a trait is tested using the average of multiple measurements, or using an observation 
at a single time point per individual, such as the baseline or the end of the study. Useful 
information may be lost during this data process. To take full advantage of the data and 
further improve power, multiple measurements per individual should be included in the 
analysis when available.  
 
Multiple measurements per individual may be collected to better understand their 
biological meaning. On the one hand, analyzing multiple measurements may reflect the 
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nature of the traits or diseases. For example, pulmonary functions are usually related to 
smoking status and pack-years, which may change over time. In pharmaceutical industry, 
the drug response is usually recorded over time or over an increase in dosage. Multiple 
measurements at different exposure levels may help in detecting the genetic association.  
 
On the other hand, it is common to collect multiple traits to characterize affected 
individuals for complex diseases. Potential misclassification may happen due to 
divergence or ambiguity in the definition of complex diseases. The risk of 
misclassification may be reduced by joint analyses of related traits. For example, there 
are different ways to define a chronic obstructive pulmonary disease (COPD) case using 
a person’s forced expiratory volume in 1 second (FEV1) and FEV1 to forced vital 
capacity ratio (FEV1/FVC). A person may be diagnosed with COPD under one definition 
(e.g. FEV1 less than 80% of its predicted value and FEV1/FVC less than its lower limit 
of normal) but not under another definition (e.g. FEV1 less than its lower limit of normal 
and FEV1/FVC less than its lower limit of normal). Misclassification may exist in a 
genetic association study when using a binary variable of COPD as the outcome. Instead, 
jointly using the continuous measurements of FEV1 and FEV1/FVC as the outcomes of 
interest may minimize the misclassification issue. 
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1.3 Dissertation Outline 
This dissertation includes 3 projects addressing different aspects of rare variant 
association studies. I developed statistical models to take advantage of multiple 
measurements in association studies. At the same time, I focus on methods that can be 
applied to family samples, thereby preventing the reduction in sample size when related 
individuals are omitted from analyses. This work involves rare variant association 
analysis, related individuals, repeated measurements or multiple traits, gene-environment 
interaction analysis, and meta-analysis.  
 
In Chapter 2, I propose a general framework, genSKAT, to deal with rare variants, 
familial correlation, and repeated measurements or multiple traits based on the Sequence 
Kernel Association Test [8] [62]. To increase the power to detect associations, we may 
analyze multiple measurements per individual when available. For complex diseases, 
multiple traits are often collected to characterize affected individuals, and a joint analysis 
of related traits may provide increased power to detect genetic associations. 
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In Chapter 3, I discuss methods to test gene-environment interaction in the genSKAT 
framework. A portion of the variation in a given trait or disease may also be due to 
environmental factors and their interactions with genetic variants. I expect this approach 
to help in the understanding of the environmental factors that modify the genetic effects 
by using multiple measurements per individual. 
 
In Chapter 4, I evaluate meta-analysis strategies to combine different types of cohorts: 
samples of unrelated individuals with one observation per person or with multiple 
observations per person, and family samples with one observation per person or with 
multiple observations per person. I perform simulation studies to estimate the type I error 
of genSKAT meta-analyses, and evaluate power when sample size and effect size change 
in different types of cohorts. I compare the power of genSKAT meta-analysis assuming 
homogeneous genetic effects, genSKAT meta-analysis assuming heterogeneous genetic 
effects, genSKAT on pooled data combining all individuals, and famSKAT meta-analysis 
assuming heterogeneity under different scenarios.  
 
In Chapter 5, I summarize the research findings and discuss future work. 
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Chapter 2 Sequence Kernel Association Test for Family Samples with Repeated 
Quantitative Measurements or Multiple Quantitative Traits 
2.1 Introduction 
Genetic loci identified by single variant association tests account for only a small 
proportion of the heritability for most complex traits and diseases. Part of the unexplained 
heritability may be due to rare variants [14]. Usually, single variant tests have low power 
when applied to rare variants. Many statistical models for rare variant association 
analysis have been proposed [2] [8] [11] [17] [22] [24] [33] [34] [36] [41] [45] [46] [48] 
[50] [51] [62] [63]. Among them, the sequence kernel association test (SKAT) has been 
shown to be a powerful method in various scenarios [62]. It is a score-based variance 
component test that allows rare variants with different directions of effects, and is 
computationally efficient because permutations are not required to evaluate statistical 
significance [10]. The family-based SKAT (famSKAT) is an extension of SKAT [8] to 
control the type I error by including familial correlation in the model. 
 
There are three main strategies to increase the power to detect associations of rare 
variants: 1) jointly analyzing multiple rare variants; 2) increasing the sample by including 
additional individuals such as family members; and 3) analyzing multiple measurements 
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per individual when available. Longitudinal data or repeated measurements are often 
available in prospective cohort studies. For complex diseases, it is common to collect 
multiple traits to characterize affected individuals, and a joint analysis of related traits 
may provide increased power to detect genetic associations.  
 
Using these three strategies, we introduce three layers of correlations: the correlation 
between variants, the correlation among family members, and the correlation between 
multiple traits or repeated measurements within each individual. Burden tests and the 
original SKAT adjust for the first layer of correlation, and famSKAT accounts for the 
first two layers of correlations. We propose a general SKAT framework (genSKAT) that 
takes all three layers of correlations into consideration in the test statistic formulation. 
Hence it is applicable to gene-based association studies with family samples, repeated 
phenotype measurements or multiple traits. When each participant has only one 
measurement, genSKAT is equivalent to SKAT when there is no familial correlation and 
to famSKAT in the presence of familial correlation.  
 
SKAT and famSKAT will have inflated type I error if correlations between repeated 
phenotype measurements or multiple traits are inappropriately ignored. In our simulation 
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studies, we show that genSKAT has the correct type I error in the scenarios evaluated. 
GenSKAT has comparable power to famSKAT using mean phenotype data. We illustrate 
our approach to evaluate the association of rare genetic variants using longitudinal 
pulmonary function traits from the Framingham Heart Study data. 
 
2.2 Method 
We assume that there are 𝑛 individuals, some of them may be related to each other. Each 
individual has 𝑚 repeated measurements or 𝑚 traits. There are 𝑝 covariates and 𝑞 rare 
variants of interest. We assume that the quantitative traits follow a linear mixed effects 
model written in matrix form as 
𝒚 = 𝑿𝜷 + 𝑮𝜸 + 𝜹 + 𝝐. 
In this model, we assume that the correlation between multiple measurements is due to 
two sources, unmeasured genetic factors and environmental factors besides the 
covariates, represented by 𝜹 and 𝝐 respectively. More specific explanations of each term 
are below.  
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The vector 𝒚 = (𝒚1, 𝒚2, … , 𝒚𝑛)
𝑇 of size 𝑛𝑚 × 1 contains the phenotype measurements, 
where 𝒚𝑖 = (𝑦𝑖1, 𝑦𝑖2, … , 𝑦𝑖𝑚) and 𝑦𝑖𝑗 denotes the 𝑗
𝑡ℎ measurement or trait of individual 𝑖. 
 
The matrix 𝑿 is an 𝑛𝑚 ×𝑚(𝑝 + 1) design matrix of covariates.  
𝑿 =
(
 
𝑰𝑚 𝑿1
𝑰𝑚 𝑿2
⋮   ⋮
𝑰𝑚 𝑿𝑛)
 , 
where 𝑰𝑚 is an 𝑚 ×𝑚 identity matrix, and  
𝑿𝑖 = (
𝒙𝑖1 𝟎 … 𝟎
𝟎 𝒙𝑖2 … 𝟎
⋮ ⋮ ⋮ ⋮
𝟎 𝟎 … 𝒙𝑖𝑚
) , 𝒙𝑖𝑗 = (𝑥𝑖𝑗1, 𝑥𝑖𝑗2, … , 𝑥𝑖𝑗𝑝), 𝑖 = 1,2, … , 𝑛, 𝑗 = 1,2, … ,𝑚.  
The vector 𝒙𝑖𝑗 contains the measurements of 𝑝 covariates for individual 𝑖 at 𝑗
𝑡ℎ 
phenotype measurement or trait. The matrix 𝑿 is written in this way to allow different 
intercepts and different covariate effects for different phenotype measurements or 
different traits. 
 
The vector 𝜷 is an 𝑚(𝑝 + 1) × 1 vector of fixed effect parameters,  
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𝜷 = (𝝁,  𝜷1, 𝜷𝟐, … , 𝜷𝑚 )
𝑇
, 
where 𝝁 = (𝜇1, 𝜇2, … ,  𝜇𝑚)
𝑇
 contains 𝑚 intercepts for 𝑚 phenotype measurements or 
traits, and 𝜷𝑗 = (𝛽𝑗1, 𝛽𝑗2, … , 𝛽𝑗𝑝)
𝑇
,  𝑗 = 1,2, … ,  𝑚 contains 𝑝 fixed effects for 𝑗𝑡ℎ 
phenotype measurement or trait. There are a total of 𝑚𝑝 covariate effects. This number 
can be reasonably reduced to 𝑝 covariate effects for repeated phenotype measurements, if 
we assume the fixed effect of the same covariate is the same for all repeated 
measurements. 
 
The matrix 𝑮 is an 𝑛𝑚 × 𝑞 genotype matrix for 𝑞 rare variants. The genotype of each 
individual repeats 𝑚 times (𝑚 rows) in this matrix. The 𝜸 is a 𝑞 × 1 vector for the 
random effects of rare variants, 𝜹 is an 𝑛𝑚 × 1 vector for the unmeasured genetic effect, 
and 𝝐 is an 𝑛𝑚 × 1 vector for residuals. We assume 𝜸, 𝜹, and 𝝐 are random, independent 
effects with  
𝜸 ~ 𝑁(𝟎, 𝜏𝑾), 
𝜹~𝑁(𝟎,𝚽⊗ 𝑨), 
𝝐~𝑁(𝟎, 𝑰𝑛⊗𝑹),   
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where 𝜏 is a corresponding variance component parameter, 𝑾 is a 𝑞 × 𝑞 diagonal weight 
matrix for the rare variants, 𝚽 is an 𝑛 × 𝑛 relationship coefficient matrix or twice the 
kinship matrix, 𝑰𝑛 is an 𝑛 × 𝑛 identity matrix, and 
𝑨 =
(
 
 
𝜎𝐴11
2 𝜎𝐴12 ⋯ 𝜎𝐴1𝑚
𝜎𝐴12 𝜎𝐴22
2 ⋯ 𝜎𝐴2𝑚
⋮        ⋮      ⋮       ⋮
𝜎𝐴1𝑚 𝜎𝐴2𝑚 ⋯ 𝜎𝐴𝑚𝑚
2
)
 
 
,  𝑹 =
(
 
 
𝜎𝐸11
2 𝜎𝐸12 ⋯ 𝜎𝐸1𝑚
𝜎𝐸12 𝜎𝐸22
2 ⋯ 𝜎𝐸2𝑚
⋮        ⋮      ⋮       ⋮
𝜎𝐸1𝑚 𝜎𝐸2𝑚 ⋯ 𝜎𝐸𝑚𝑚
2
)
 
 
. 
Here 𝑨 is an 𝑚×𝑚 polygenic covariance matrix and 𝑹 is an 𝑚 ×𝑚 error covariance 
matrix for 𝑚 phenotype measurements or traits. The diagonal elements are the variances 
of each measurement due to unmeasured genetic information or error. The off-diagonal 
elements are the covariance between two measurements due to unmeasured genetic 
information or error. The symbol ⊗ denotes the Kronecker product. For multiple traits, 
some pairs of traits may be more correlated than others. The same applies for repeated 
measurements, where adjacent measurements are expected to be more correlated. Thus 
we use the Kronecker product to accommodate such correlation patterns. 
 
We want to test whether a set of rare variants is associated with a quantitative phenotype. 
In our parameter setting, we are interested in testing 
𝐻0: 𝜸 = 𝟎 𝑣𝑠.  𝐻1: 𝜸 ≠ 𝟎. 
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As in Wu et al [62], we test the following null hypothesis instead:  
𝐻0: 𝜏 = 0 𝑣𝑠.  𝐻1:  𝜏 ≠ 0. 
The phenotypic variance is denoted as 
𝚺 = 𝑉𝑎𝑟(𝒚) = 𝜏𝑮𝑾𝑮𝑇 +𝚽⊗𝑨+ 𝑰𝑛⊗𝑹. 
Under the null hypothesis, 𝒚 = 𝑿𝜷 + 𝜹 + 𝝐, estimates of the phenotypic variance and the 
effect of the genetic variants can be written as 
?̂? = 𝚽⊗ ?̂? + 𝑰𝑛⊗ ?̂?, 
?̂? = (𝑿𝑇?̂?−1𝑿)
−1
𝑿𝑇?̂?−1𝒚. 
The maximum likelihood estimators of ?̂?, ?̂?, and ?̂? are obtained under the null 
hypothesis. This is a major advantage of score tests because parameters do not need to be 
estimated under the alternative hypothesis, thus reducing the computational burden.  
 
To obtain a variance component score test statistic, we need to take the derivative of the 
log likelihood for this linear mixed effects model with respect to 𝜏. Following the same 
rationale as in the famSKAT statistic [8], the genSKAT score statistic can be written as 
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𝑄 = (𝒚 − 𝑿?̂?)
𝑇
?̂?−1𝑮𝑾𝑮𝑇?̂?−1(𝒚 − 𝑿?̂?). 
Under the null hypothesis,  
𝑄~∑𝜆𝑖𝜒1,𝑖
2
𝑞
𝑖=1
, 
where 𝜆𝑖 are the eigenvalues of 𝑾
1/2𝑮𝑇?̂?−1𝐏0?̂?
−1𝑮𝑾1/2, with  
𝑷0 = 𝑉𝑎𝑟(𝒚 − 𝑿?̂?) = ?̂? − 𝑿(𝑿
𝑇?̂?−1𝑿)
−1
𝑿𝑇, 
and 𝜒1,𝑖
2  are independent 𝜒1
2 random variables. The p-value can be computed by the 
Davies method [10] from the R package CompQuadForm [12] or the Kuonen’s 
saddlepoint method [30] from the R package survey [39]. The Davies’ method is slightly 
faster than the saddlepoint approximation. Chen et al. recommended the use of the 
Kuonen’s saddlepoint method when p-values are expected to be very small because the 
Davies’ method is less accurate for small p-values [8]. 
 
The null model and test statistic are in the same form as famSKAT, while the parameter 
settings are defined in a different way. When each individual only has 1 phenotype 
observation (𝑚 = 1), genSKAT is equivalent to famSKAT. Additionally when there is 
no correlation between individuals, 𝑨 = 𝟎, genSKAT is equivalent to SKAT.  
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2.3 Simulation Studies 
2.3.1 Type I Error 
2.3.1.1 Simulation Design 
We performed simulations to evaluate the type I error of genSKAT.  We also included 
other tests, SKAT, famSKAT and the family based burden test (famBT), in our type-I 
error evaluation. For SKAT, we only included the unrelated individuals. For SKAT, 
famSKAT and famBT, we used baseline phenotype measurement, or the average of 
phenotype measurements. We also checked the type I error of famSKAT on full data 
without adjusting for the correlation between multiple measurements.  
 
We simulated 100 genotype datasets for 250 nuclear families with 2 parents and 2 
offspring, for a total of 1000 individuals per study. We included 20 variants with minor 
allele frequencies from 0.002 to 0.04. We first generated latent variables from the 
multivariate normal distribution with a first order autoregressive covariance structure. We 
set the parameter in the covariance structure to be 0.98, 0.9, and 0.8 to simulate the high, 
moderate, and low LD situations. Then the latent variables were dichotomized at specific 
quantiles decided by the minor allele frequencies to generate the haplotypes for founders. 
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The haplotypes were passed down to offspring without recombination according to 
Mendel’s segregation law.  
 
Three scenarios were considered for the phenotype simulation: each individual had 2, 3, 
or 4 repeated phenotype measurements. For each scenario, we simulated 10,000 
phenotype datasets with the formula 
𝒚 = 0.5𝒙1 + 0.5𝒙2 + 𝜹 + 𝝐, 
where 𝒙1~𝑁(𝟎, 𝟏) and 𝒙2~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(0.5) were two covariates. In real data, 𝒙1 can be 
considered as a standardized continuous variable and 𝒙2 can be considered as a binary 
variable like gender. The vectors 𝜹 and 𝝐 were generated from multivariate normal 
distributions 𝑁(𝟎,𝚽⊗ 𝑨) and 𝑁(𝟎, 𝑰𝑛⊗𝑹) respectively, where 𝚽 was the relationship 
coefficient matrix for the 250 nuclear families, and 
𝑨 = (
1.60 0.96
0.96 1.60
) , (
1.60 0.96 0.96
0.96 1.60 0.96
0.96 0.96 1.60
) ,(
1.60 0.96 0.96 0.96
0.96 1.60 0.96 0.96
0.96 0.96 1.60 0.96
0.96 0.96 0.96 1.60
), 
𝑹 = (
2.40 1.20
1.20 2.40
) , (
2.40 1.20 0.96
1.20 2.40 1.20
0.96 1.20 2.40
) , (
2.40 1.20 0.96 0.72
1.20 2.40 1.20 0.96
0.96 1.20 2.40 1.20
0.72 0.96 1.20 2.40
), 
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for each phenotype simulation scenario. Here we set the heritability to be 0.4, the 
phenotype variance to be 4, the pairwise genetic correlation to be 0.6, and the error 
correlation between adjacent measurements to be 0.5. We let the error correlation 
between farther measurements decrease by 0.1. The correlation matrix for 4 
measurements was 
(
1.00 0.54 0.48 0.42
0.54 1.00 0.54 0.48
0.48 0.54 1.00 0.54
0.42 0.48 0.54 1.00
). 
Because we assumed the outcomes were repeated measurements of the same trait in these 
simulations, we set the unmeasured genetic variance and residual variance to be the same 
across measurements, which were the diagonal elements in 𝑨 and 𝑹. We also set the off-
diagonal elements in matrix 𝑨 to be the same, assuming the unmeasured genetic 
covariance between measurement pairs stayed constant. We allowed smaller residual 
covariance for measurements further apart in matrix 𝑬. These assumptions were made to 
reduce the number of estimated parameters in our simulations. They were not required by 
the genSKAT method itself. Using unstructured covariance introduce more parameters 
and may cause the estimates to be unstable. For the type I error simulation, there were no 
genetic effects in this model (𝜸 = 𝟎). 
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When evaluating p-values, we estimated 𝑨 and 𝑹 from the output of the Sequential 
Oligogenic Linkage Analysis Routines (SOLAR) software, and used the Wu weights for 
the weight matrix 𝑾. The empirical type I error of genSKAT and the other four methods 
were calculated at α levels of 0.01, 0.001 and 0.0001. The type I error was equal to the 
proportion of p-values less than or equal to the corresponding α level in the 1 million 
simulated datasets (100 genotypes × 10,000 phenotypes). 
 
2.3.1.2 Simulation Results 
FamSKAT has inflated type I error when it was applied to the full data without adjusting 
for correlations between multiple measurements per person (Table 1). Table 2-Table 4 
shows the empirical type I errors when genSKAT applied to full data, SKAT applied to 
baseline or mean phenotype data of unrelated subjects, and famSKAT and famBT applied 
to baseline or mean phenotype data of family data. GenSKAT considered all 1,000 
individuals with all data points. The total number of observations was 2,000, 3,000, or 
4,000 when the number of measurements per person was 2, 3, or 4. FamSKAT and 
famBT was performed on all 1,000 individuals using baseline data or the mean of the 
measurements. The total number of observations was 1,000. The original SKAT only 
included unrelated individuals (unrSKAT), where the sample size and the total number of 
observations were 500. The type I errors were calculated in three different LD scenarios 
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and three different numbers of observations per individual. In our simulations, we 
observe that genSKAT has correct type I errors.  This is also true for unrSKAT, 
famSKAT and famBT using mean or baseline phenotype data. 
 
Table 1 Inflated type I error for famSKAT ignoring correlations between multiple 
measurements 
α level 
# of measurements 
2 3 4 
0.01 0.04077 0.08574 0.13186 
0.001 0.00854 0.02425 0.04611 
0.0001 0.00017 0.00719 0.01641 
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Table 2 Type I errors for genSKAT and other approaches (α=0.01) 
LD Model 
# of measurements 
2 3 4 
Low  genSKAT All 0.0098 0.0097 0.0097 
 famSKAT Baseline 0.0095 0.0095 0.0095 
 Mean 0.0097 0.0096 0.0095 
 unrSKAT Baseline 0.0095 0.0095 0.0095 
 Mean 0.0096 0.0095 0.0096 
 famBT Baseline 0.0101 0.0101 0.0101 
 Mean 0.0100 0.0099 0.0100 
Moderate genSKAT All 0.0099 0.0101 0.0099 
 famSKAT Baseline 0.0100 0.0100 0.0100 
 Mean 0.0100 0.0100 0.0100 
 unrSKAT Baseline 0.0098 0.0098 0.0098 
 Mean 0.0100 0.0099 0.0100 
 famBT Baseline 0.0100 0.0100 0.0100 
 Mean 0.0100 0.0099 0.0099 
High genSKAT All 0.0100 0.0099 0.0099 
 famSKAT Baseline 0.0098 0.0098 0.0098 
 Mean 0.0099 0.0100 0.0099 
 unrSKAT Baseline 0.0096 0.0096 0.0096 
 Mean 0.0097 0.0096 0.0096 
 famBT Baseline 0.0100 0.0100 0.0100 
 Mean 0.0098 0.0100 0.0099 
The type I error was equal to the proportion of p-values less than or equal to the 
corresponding α level in the 1 million simulated datasets. 
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Table 3 Type I errors for genSKAT and other approaches (α=0.001) 
LD Model 
# of measurements 
2 3 4 
Low  genSKAT All 0.0010 0.0010 0.0010 
 famSKAT Baseline 0.0009 0.0009 0.0009 
 Mean 0.0010 0.0010 0.0010 
 unrSKAT Baseline 0.0009 0.0009 0.0009 
 Mean 0.0009 0.0009 0.0009 
 famBT Baseline 0.0010 0.0010 0.0010 
 Mean 0.0010 0.0011 0.0010 
Moderate genSKAT All 0.0010 0.0010 0.0010 
 famSKAT Baseline 0.0010 0.0010 0.0010 
 Mean 0.0010 0.0010 0.0010 
 unrSKAT Baseline 0.0009 0.0009 0.0009 
 Mean 0.0009 0.0009 0.0009 
 famBT Baseline 0.0010 0.0010 0.0010 
 Mean 0.0010 0.0010 0.0010 
High genSKAT All 0.0010 0.0010 0.0010 
 famSKAT Baseline 0.0010 0.0010 0.0010 
 Mean 0.0010 0.0010 0.0010 
 unrSKAT Baseline 0.0009 0.0009 0.0009 
 Mean 0.0009 0.0009 0.0009 
 famBT Baseline 0.0010 0.0010 0.0010 
 Mean 0.0010 0.0010 0.0011 
The type I error was equal to the proportion of p-values less than or equal to the 
corresponding α level in the 1 million simulated datasets 
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Table 4 Type I errors for genSKAT and other approaches (α=0.0001) 
LD Model 
# of measurements 
2 3 4 
Low  genSKAT All 0.00010 0.00010 0.00010 
 
famSKAT Baseline 0.00009 0.00009 0.00009 
 Mean 0.00010 0.00009 0.00009 
 unrSKAT Baseline 0.00009 0.00009 0.00009 
 Mean 0.00009 0.00009 0.00009 
 famBT Baseline 0.00009 0.00009 0.00009 
 Mean 0.00010 0.00011 0.00011 
Moderate genSKAT All 0.00010 0.00010 0.00010 
 famSKAT Baseline 0.00009 0.00009 0.00009 
 Mean 0.00009 0.00010 0.00009 
 unrSKAT Baseline 0.00009 0.00009 0.00009 
 Mean 0.00009 0.00009 0.00009 
 famBT Baseline 0.00011 0.00011 0.00011 
 Mean 0.00011 0.00010 0.00011 
High genSKAT All 0.00010 0.00010 0.00009 
 famSKAT Baseline 0.00009 0.00009 0.00009 
 Mean 0.00009 0.00009 0.00009 
 unrSKAT Baseline 0.00009 0.00009 0.00009 
 Mean 0.00010 0.00009 0.00009 
 famBT Baseline 0.00009 0.00009 0.00009 
 Mean 0.00010 0.00011 0.00011 
The type I error was equal to the proportion of p-values less than or equal to the 
corresponding α level in the 1 million simulated datasets 
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2.3.2 Power 
2.3.2.1 Simulation Design 
We compared the power of genSKAT, famSKAT and famBT. Repeated measurements 
were simulated, so that we could use the average phenotype measurement as the outcome 
variable for famSKAT and famBT. We applied genSKAT to the full data. 
 
We generated 100 genotype datasets in the same way as for the type I error simulation. 
When generating the phenotype, we also considered three scenarios: each individual had 
2, 3, or 4 phenotype measurements. For each scenario, 1,000 phenotype datasets were 
simulated with the equation 
𝒚 = 0.5𝒙1 + 0.5𝒙2 + 𝑮𝜸 + 𝜹 + 𝝐,  
where 𝒙1, 𝒙2, 𝜹, and 𝝐 were generated in the same way as in the type I error simulation. 
The vector 𝜸 contains the random effects of causal rare variants. We randomly selected 
80% of the rare variants as causal variants, and randomly assigned negative effect size to 
0% or 50% of the causal variants. The absolute value of effect size 𝛾𝑙 for 𝑙
𝑡ℎ variant is 
defined similarly as in Chen’s famSKAT paper [8], 
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|𝛾𝑙| = √
𝑐/𝒗′𝑫𝒗
2𝑀𝐴𝐹𝑙(1−𝑀𝐴𝐹𝑙)
, 
where c is a constant. In this formula, we set 𝑐 to 0.05 when all causal variants’ effect 
sizes are positive and 0.5 when half of the causal variants’ effect sizes are negative. The 
matrix 𝑫 is a first order auto-regressive matrix for the rare variants and 𝒗 is a direction 
vector consisting of ±1.  
 
When evaluating the p-values, we estimated the covariance matrices 𝑨 and 𝑹 from the 
output of the SOLAR software, and used the Wu weights in the weight matrix 𝑾. We set 
the polygenic covariance between measurements to be the same. The power was equal to 
the proportion of p-values less than or equal to 0.001 in the 100,000 datasets.  
 
2.3.2.2 Simulation Results 
Figure 1 shows power simulation results for different numbers of repeated measurements 
per individual. The left panel in Figure 1 corresponds to the scenario when all causal rare 
variants have positive effect sizes. In this case, famBT is more powerful than famSKAT 
and genSKAT. The right panel in Figure 1 shows the results when half of the causal rare 
variants have negative effect sizes. FamBT has lower power because it cannot handle 
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variants with opposite directions of effect sizes well. FamSKAT and genSKAT do not 
dramatically lose power when there are opposite direction of interaction effects. If we 
don’t have prior information about the direction of genetic effects, we recommend 
genSKAT or famSKAT over famBT. GenSKAT and famSKAT on the average of 
measurements have similar power. The power of genSKAT and famSKAT increases with 
the number of repeated phenotype measurements. 
 
Figure 1 Power comparisons of genSKAT, famSKAT, and famBT 
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2.4 Application to Framingham Heart Study Data 
To show that genSKAT can handle missing values and complicated family structure in 
real data, we illustrated our approach by applying genSKAT to evaluate the association 
between pulmonary function score FEV1/FVC and genetic variants in two genes, 
ADAM19 and HTR4. Common variants rs2277027 and rs1422795 in ADAM19, and 
rs11168048 and rs7735184 in HTR4 have been reported to be associated to lung function 
measurements in a previous genome-wide association study [37].We compared the 
results from genSKAT, famSKAT and famBT. 
 
For ADAM19 and HTR4, we used the genotype data from Framingham Cohorts for 
Heart and Aging Research in Genomic Epidemiology Targeted Sequencing Project 
(CHARGE-S). Genes previously shown to be related to some phenotypes were selected 
for deep re-sequencing as part of the CHARGE-S project. We only analyzed polymorphic 
rare variants with MAF less than 5%. For ADAM19, we additionally restricted to be 
within ±1kb of the reported common variants rs2277027 (region 1) and rs1422795 
(region 2). For HTR4, we included rare variants within ±6kb of rs11168048 (region 3) 
and ±7kb of rs7735184 (region 4). We set different gene region lengths in order to 
include at least 3 rare variants in each region. 
33 
 
 
 
We used phenotypes and covariates data from Framingham Heart Study offspring cohort 
at exams 5, 6, and 7. We performed genSKAT on all data points, while famSKAT and 
famBT were applied to the baseline data. Similar to a previous longitudinal CHARGE-S 
study on FEV1/FVC [57], we adjusted the analyses for age, sex, height, smoking status, 
pack-years, and principal components.  
 
Table 5 and Table 6 show the p-values of the association tests for each region. We 
compare the p-values to an adjusted significance threshold for multiple tests by 
Bonferroni correction, which is 0.05/4=0.0125. For the 4 regions in ADAM19 and HTR4, 
no statistically significant associations are detected. Table 5 and Table 6 also show that 
far fewer observations were used by famSKAT and famBT compared to genSKAT. Note 
that not every individual has measurements at all 3 exams, so the number of observations 
is less than 3 times the total sample size in genSKAT. This application shows that 
genSKAT can handle missing values. The individuals in this Framingham Heart Study 
data also have more complicated familial correlations than the nuclear families in our 
simulation studies.  
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Table 5 Application of genSKAT to FEV1/FVC 
Gene Chr Region N # of observations # of variants p-value 
ADAM19 5 
Region 1 952 2314 10 0.3173 
Region 2 952 2314 9 0.3224 
HTR4 5 
Region 3 952 2314 13 0.0134 
Region 4 952 2314 3 0.8583 
Region 1: rs2277027±1kb; region 2: rs1422795±1kb; region 3: rs11168048±6kb; region 
4: rs7735184±7kb. 
 
 
Table 6 Application of famSKAT and famBT to FEV1/FVC 
Gene Chr Region 
# of 
observations 
# of 
variants 
famSKAT 
p-value 
famBT 
p-value 
ADAM19 5 
Region 1 952 10 0.8698 0.6305 
Region 2 952 9 0.6488 0.7293 
HTR4 5 
Region 3 952 13 0.8168 0.4621 
Region 4 952 3 0.2757 0.4589 
Region 1: rs2277027±1kb; region 2: rs1422795±1kb; region 3: rs11168048±6kb; region 
4: rs7735184±7kb. 
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2.5 Discussion 
In our research, we proposed a general SKAT framework that can be used to analyze 
family data, multiple phenotype measurements or multiple traits. GenSKAT is an 
extension of SKAT [62] and famSKAT [8] which additionally accounts for correlations 
between multiple measurements within each individual. GenSKAT is equivalent to 
famSKAT when only 1 observation per individual is available, and is equivalent to 
SKAT if there is also no correlation between individuals. We showed that genSKAT has 
correct type I error for family data with repeated quantitative measurements or multiple 
quantitative traits in the scenarios evaluated. To avoid inflated type I error, famSKAT 
and famBT need to be applied to the baseline data or the average of phenotype 
measurements. Additionally, samples analyzed by SKAT need to be restricted to 
unrelated individuals. FamBT has lower power when casual variants have opposite 
direction of effects. GenSKAT and famSKAT do not suffer from such drastic power loss 
when causal variants have opposite direction of effects. In real data, when no prior 
information about the true direction of the genetic effects is available, we recommend 
genSKAT or famSKAT over burden tests. GenSKAT and famSKAT on the average of 
measurements have similar power in our simulations. In real data analyses, it is usually 
not appropriate to take the average of multiple traits or the average of some covariates, 
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e.g. smoking status and pack-years. In these cases, it is hard to interpret the results of 
applying famSKAT on the average of measurements.  
 
We applied genSKAT to 4 gene regions that contain common variants previously shown 
to be associated with FEV1/FVC in large GWAS [37]. Because the common variants 
only explain part of the heritability, we investigated whether the rare variants in these 
genes are related to the trait. We used genotype data from the CHARGE-S project with 
rare variants from deep-sequenced targeted gene regions. We noted that the sample size 
in the Framingham Heart Study alone, even with repeated measurements, was much 
smaller than the sample size in the previous GWAS. We did not detect any significant 
associations between FEV1/FVC and the rare variants in these gene regions. In the 
Framingham Heart Study data, some phenotype or covariates measurements were 
missing for some individuals. The sample also had complex family structures. This 
application showed that genSKAT is a general and flexible approach that can be applied 
to complex data in real life. 
 
Genetic sequencing has become faster and cheaper with the development of new 
technologies. Deep sequencing data are becoming available for cohorts with family 
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structure as well as longitudinal measurements. For instance, in Framingham Heart 
Study, there are participants from 3 generations. For each generation, there are multiple 
exams per person. With rare variants being sequenced from projects like CHARGE-S and 
Exome Chip projects, detection of novel gene regions associated with various traits using 
genSKAT becomes possible.  GenSKAT may help to better understand diseases that are 
characterized by more than one phenotype. For example, as a complex disease, chronic 
obstructive pulmonary diseases (COPD) is usually diagnosed by FEV1 and FEV1/FVC. 
Joint analysis of these two traits in the same model using genSKAT may identify novel 
genes associated with COPD.  
 
Similar to SKAT and famSKAT, genSKAT can be used to analyze common variants or a 
combination of common variants and rare variants. Using external weights for rare 
variants based on prior information can potentially further increase the power. The 
genSKAT statistic can be combined with other test statistics to create robust approaches 
like the SKAT-O method [33].  
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Chapter 3 Gene-Environment Interaction Test for Family Samples with 
Repeated Quantitative Measurements or Multiple Quantitative Traits 
3.1 Introduction 
As previously mentioned, the genetic loci identified by single variant association tests 
account for only a small proportion of the heritability for most complex traits and 
diseases. In Chapter 2, we discussed that part of the heritability could be due to rare 
variants and proposed a general framework for a rare variant association test called 
genSKAT. In this chapter, we discuss another possible explanation for the unexplained 
heritability, gene by environment interaction (G-E interaction). There have been studies 
showing G-E interaction effects contribute to a portion of phenotypic variation [18] [21] 
[53]. Different lifestyles, treatments, drug dosages, or exposures may have very different 
effects on the outcome of interest for individuals with different genotypes. For example, 
the protective effect of ADH7 variants for oesophageal cancer is due to an interaction 
with alcohol consumption [5]. There is an increasing interest in studying the interactive 
effects of environment factors and different genotypes.  
 
Several statistical methods to test interactions between common variants and environment 
have been proposed. Manning et al. proposed jointly estimating genetic main effects and 
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G-E interation effects for meta-analysis [42]. Moreno-Macias et al. discussed G-E 
interaction tests for a single measurement per person, e.g. OLR and FBAT, and for 
longitudinal measures, e.g. OLMM and two-step modeling approach [44]. The single 
variant G-E tests may lack power if directly applied to test interactions between a rare 
variant and environment. Chen et al. discussed G-E interaction tests and joint test of G 
and G-E interaction for rare variants under the SKAT framework [7]. In some studies, 
each individual may have more than one measurement, which provides more information. 
If we can take advantage of all available data points, we may be able to further improve 
the power of interaction tests. For complex diseases, the environment exposure and its 
interaction with genes may affect more than one trait. Moreover, the gene effects may be 
different at different time points. Therefore, a gene-environment interaction test under the 
genSKAT framework may offer improved power to identify genes playing an important 
role in trait regulation or disease risk. 
 
There are two main purposes of including G-E interaction term in a statistical model. 
First, the power to detect a genetic effect may be increased when a gene-environment 
interaction exists and is correctly included in the model. In this situation, we jointly test 
the main effect of rare variants and the gene-environment interaction effect. Thus it is a 
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multi-dimensional test. Second, detecting a significant interaction effect itself may help 
in understanding the disease or trait mechanism. In this scenario, we are primarily 
interested in testing the interaction term.  
 
In our simulation studies we showed that SKAT and famSKAT for G-E interaction 
effects obtain the correct type I error if being applied to the average of multiple available 
measurements or when using one observation per individual. The G-E interaction test in 
the genSKAT framework has the correct type I error in the scenarios evaluated. 
GenSKAT for G-E interaction effects has comparable power to famSKAT for G-E 
interaction effects using mean phenotype data. We illustrate our approach to evaluate G-
E effects of rare genetic variants on pulmonary function traits from the Framingham 
Heart Study. 
 
3.2 Methods 
We assume that there are 𝑛 individuals, some of whom may be related, with 𝑚 repeated 
measurements or 𝑚 traits. There are 𝑝 covariates and 𝑞 rare variants of interest. Assume 
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the quantitative traits follow a linear mixed effects model that can be written in matrix 
form as 
𝒚 = 𝑿𝜷 + 𝑮𝜸 + 𝑬𝑮𝜼 + 𝜹 + 𝝐. 
Correlation between multiple measurements is due to two sources, the unmeasured 
genetic factors and the environmental factors, which are represented by 𝜹 and 𝝐 
respectively. In this model, following the same definitions as in section 2.2, 𝒚 is a 𝑛𝑚 ×
1 phenotype vector, 𝑿 is an 𝑛𝑚 ×𝑚(𝑝 + 1) covariate matrix, 𝜷 is an 𝑚(𝑝 + 1) × 1 
vector of fixed effect parameters, 𝑮 is an 𝑛𝑚 × 𝑞 genotype matrix, 𝑾 is a 𝑞 × 𝑞 diagonal 
weight matrix for the rare variants, 𝜹 is an 𝑛𝑚 × 1 vector for the unmeasured genetic 
effect, 𝜹~𝑁(𝟎,𝚽⊗ 𝑨), and 𝝐 is an 𝑛𝑚 × 1 vector for the residual, 𝝐~𝑁(𝟎, 𝑰𝑛⊗𝑹). 
 
Additionally, 𝑬 is a matrix for an environment factor that may have an interaction effect 
with the genotypes. We assume that the elements in matrix 𝑬 are also in the covariate 
matrix 𝑿. More specifically, 𝑬 is an 𝑛𝑚 × 𝑛𝑚 diagonal matrix,  
𝑬 = 𝑑𝑖𝑎𝑔(𝑧1, 𝑧2, … , 𝑧n) , 
where 𝑧𝑖 = 𝑑𝑖𝑎𝑔(𝑥𝑖1𝑣, 𝑥𝑖2𝑣, … , 𝑥𝑖m𝑣), and 𝑥𝑖𝑗𝑣 is the 𝑗
𝑡ℎ measurement of 𝑣𝑡ℎ covariate 
of individual 𝑖. We define 𝑬 in this way to keep our model in matrix format and 
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consistent with the model used to test main effects in Chapter 2. The matrix 𝑬 is a sparse 
matrix, so matrix operation functions designed for sparse matrices can be used in 
computing to increase efficiency and lower the memory usage. 
 
The vector 𝜸 of size 𝑞 × 1 contains the main effects of rare variants, which can be treated 
as fixed effects or random effects. If the main effects are treated as random effects, we 
assume 𝜸 ~ 𝑁(𝟎, 𝜏𝑾), where 𝑾 is a 𝑞 × 𝑞 diagonal weight matrix for the rare variants 
and τ is the corresponding variance component parameter. 
 
The vector 𝜼 of size 𝑞 × 1 contains the gene-environment interaction effects. We assume 
𝜸, 𝜼, 𝜹 and 𝝐 are independent, random effects with  
𝜼~𝑁(𝟎, ξ?̃?), 
where 𝜉 is the corresponding variance component parameter and ?̃? is a 𝑞 × 𝑞 diagonal 
weight matrix for the rare variants. The matrix ?̃? can be different from 𝑾. Usually it is 
reasonable to use the same weight matrix 𝑾 for both 𝜼 and 𝜸 because the same set of rare 
variants are analyzed for both main effects and interaction effects. 
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In this project, we discuss the tests for the null hypothesis with respect to the interaction 
effect only. The hypotheses can be written as 
𝐻0: 𝜼 = 𝟎 𝑣𝑠.  𝐻1: 𝜼 ≠ 𝟎. 
It is equivalent to the testing of 
𝐻0: 𝜉 = 0 𝑣𝑠.  𝐻1:  𝜉 ≠ 0. 
 
Scenario 1. When the genetic main effects 𝜸 are treated as fixed effects, under the null 
hypothesis, 
𝒚 = 𝑿𝜷 + 𝑮√𝑾𝜸 + 𝜹 + 𝝐. 
We define two new matrices as 
𝑯 = (𝑿, 𝑮√𝑾)
𝒏𝒎×[𝒎(𝒑+𝟏)+𝒒]
, 𝜽 = (
𝜷
𝜸
)
[𝒎(𝒑+𝟏)+𝒒]×𝟏
. 
Then the model under null hypothesis in this scenario can be re-written as 
𝒚 = 𝑯𝜽 + 𝜹 + 𝝐, 
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𝜹~𝑁(𝟎,𝚽⊗ 𝑨), 
𝝐~𝑁(𝟎, 𝑰𝑛⊗𝑹). 
The phenotypic variance is written as 
𝚺 = 𝑉𝑎𝑟(𝒚) = 𝜉(𝑬𝑮)𝑾(𝑬𝑮)𝑇 +𝚽⊗𝑨+ 𝑰𝑛⊗𝑹. 
Under the null hypothesis,  
?̂? = 𝚽⊗ ?̂? + 𝑰𝑛⊗ ?̂?, 
?̂? = (𝑯𝑇?̂?−1𝑯)
−1
𝑯𝑇?̂?−1𝒚. 
The maximum likelihood estimates of ?̂?, ?̂?, and ?̂? are obtained under the null hypothesis 
of no gene-environment interaction. 
 
Following the same rationale as in the genSKAT main effect test statistic, the variance 
component score test statistic for G-E interaction effects can be written as 
𝑄𝐹𝐼𝑋 = (𝒚 − 𝑯?̂?)
𝑇
?̂?−1(𝑬𝑮)𝑾(𝑬𝑮)𝑇?̂?−1(𝒚 − 𝑯?̂?). 
Under the null hypothesis,  
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𝑄𝐹𝐼𝑋~∑𝜆𝑙𝜒1,𝑙
2
𝑞
𝑙=1
, 
where 𝜒1,𝑙
2  are independent 𝜒1
2 random variables and 𝜆𝑙 are the eigenvalues of the matrix 
𝑾
1
2(𝑬𝑮)𝑇?̂?−1𝐏0?̂?
−1(𝑬𝑮)𝑾
1
2, 
with 𝑷0 = 𝑉𝑎𝑟(𝒚 − 𝑯?̂?) = ?̂? − 𝑯(𝑯
𝑇?̂?−1𝑯)
−1
𝑯𝑇. 
 
Scenario 2. If the genetic main effects 𝜸 are treated as random effects, under the null 
hypothesis, 
𝒚 = 𝑿𝜷 + 𝑮𝜸 + 𝜹 + 𝝐, 
𝜸 ~ 𝑁(𝟎, 𝜏𝑾) 
𝜹~𝑁(𝟎,𝚽⊗ 𝑨), 
𝝐~𝑁(𝟎, 𝑰𝑛⊗𝑹). 
The phenotypic variance is  
𝚺 = 𝑉𝑎𝑟(𝒚) = 𝜏𝑮𝑾𝑮𝑇 + 𝜉(𝑬𝑮)𝑾(𝑬𝑮)𝑇 +𝚽⊗𝑨+ 𝑰𝑛⊗𝑹. 
Under the null hypothesis,  
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?̂? = ?̂?𝑮𝑾𝑮𝑇 +𝚽⊗ ?̂? + 𝑰𝑛⊗ ?̂?, 
?̂? = (𝑿𝑇?̂?−1𝑿)
−1
𝑿𝑇?̂?−1𝒚. 
The maximum likelihood estimates of ?̂?, ?̂?, ?̂?, and ?̂? are obtained under the null 
hypothesis.  
 
Following the same rationale as in the genSKAT main effect test statistic, the variance 
component score test statistic for a test of interaction can be written as 
𝑄𝑅𝐴𝑁 = (𝒚 − 𝑿?̂?)
𝑇
?̂?−1(𝑬𝑮)𝑾(𝑬𝑮)𝑇?̂?−1(𝒚 − 𝑿?̂?). 
Under the null hypothesis,  
𝑄𝑅𝐴𝑁~∑𝜆𝑙𝜒1,𝑙
2
𝑞
𝑙=1
, 
where 𝜒1,𝑙
2  are independent 𝜒1
2 random variables and 𝜆𝑙 are the eigenvalues of the matrix 
𝑾
1
2(𝑬𝑮)𝑇?̂?−1𝐏0?̂?
−1(𝑬𝑮)𝑾
1
2, 
where 𝑷0 = 𝑉𝑎𝑟(𝒚 − 𝑿?̂?) = ?̂? − 𝑿(𝑿
𝑇?̂?−1𝑿)
−1
𝑿𝑇. 
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The p-value can be computed by the Davies method [10] from the R package 
CompQuadForm [12] or the Kuonen’s saddlepoint method [30] from the R package 
survey [39]. Chen et al. recommended the latter because Davies’ method is less accurate 
for small p-values [8]. 
 
When each individual only has 1 observation, that is 𝑚 = 1, the dimension of 𝑬 is 
reduced to 𝑛 × 𝑛. The test statistic and its distribution are the same as those in famSKAT 
for G-E interaction effects. Additionally when all individuals are unrelated, that is 𝜹 =
𝟎 or 𝑨 = 𝟎, the test statistic and its distribution are the same as those in the interaction 
test in SKAT. 
 
3.3 Simulation Studies 
3.3.1 Type I Error 
3.3.1.1 Simulation Design 
We performed simulations to evaluate the type I error of genSKAT for interaction effects 
and compare it with other methods. When we assume the genetic main effects are random 
effects, the test statistic and its distribution are in the same form as the scenario assuming 
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fixed genetic main effects. In our simulations we treated the genetic main effects as fixed 
effects and assumed the outcomes were repeated measurements of the same trait. We 
compared the type I error of genSKAT to famSKAT and famBT for interaction effects. 
For genSKAT, we included all individuals with all data points. For famSKAT and 
famBT, we used baseline phenotype measurement, or the average of repeated phenotype 
measurements.  
 
In the same way as in section 2.3.1.1, we simulated 100 genotype datasets for 500 nuclear 
families with 2 parents and 2 offspring, for a total of 2,000 individuals per study. Three 
scenarios were considered for the phenotype simulation: each individual had 2, 3, or 4 
repeated phenotype measurements. For each scenario, we simulated 1,000 phenotype 
datasets with the formula 
𝒚 = 0.5𝒙1 + 0.5𝒙2 + 𝑮𝜸 + 𝜹 + 𝝐, 
where 𝒙1~𝑁(𝟎, 𝟏) and 𝒙2~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(0.5) were two covariates. In real data, 𝒙1 can be 
considered as a standardized continuous variable, and 𝒙2 can be considered as a binary 
variable like gender. We assume there are genetic main effects but no interaction effects. 
For the genetic main effects, we randomly selected 80% of the rare variants as causal 
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variants, and randomly assigned negative effect size to 0% or 50% of the causal variants. 
The effect sizes were generated in the same way as in section 2.3.2.1.  
 
Using the same definition of 𝑨 and 𝑹 in section 2.3.1.1, 𝜹 and 𝝐 were generated from 
multivariate normal distribution 𝑁(𝟎,𝚽⊗ 𝑨), and 𝑁(𝟎, 𝑰𝑛⊗𝑹),  where 𝚽 is the 
relationship coefficient matrix or twice the kinship matrix of the 500 nuclear families. As 
mentioned previously, we assumed outcomes were repeated measurements of the same 
trait in these simulations. Therefore we set the unmeasured genetic variance and residual 
variance to be the same across measurements, which were the diagonal elements in 𝑨 and 
𝑹. We also let the unmeasured genetic covariance between measurement pairs, the off-
diagonal elements in 𝑨, stay constant. These assumptions were made to reduce the 
number of estimated parameters in our simulations. Theoretically they were not required 
by the genSKAT method itself. Using unstructured covariance introduce more parameters 
and may cause the estimates to be unstable. When computing the genSKAT statistic, we 
calculated 𝑨 and 𝑹 from the output of the Sequential Oligogenic Linkage Analysis 
Routines (SOLAR) software, and used the Wu weights for the both main effects and 
interaction effects. The empirical type I error of genSKAT and the other four methods 
were calculated at α levels of 0.01 and 0.001. The type I error was equal to the proportion 
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of p-values less than or equal to the corresponding α level in the 100,000 simulated 
datasets (100 genotype datasets × 1,000 phenotype datasets). 
 
3.3.1.2 Simulation Results 
Table 7-Table 10 show the empirical type I errors of genSKAT, famSKAT, and famBT 
for G-E interaction effects when all genetic main effects are positive or half of the genetic 
main effects are negative. Because all three methods account for familial correlations, 
they were performed on all individuals. FamSKAT and famBT were applied to the 
baseline data, and mean data, while genSKAT was applied to the repeated measurements. 
The type I errors were calculated for three different LD scenarios and three different 
numbers of observations per individual. Our simulation studies show that the interaction 
test in genSKAT has correct type I errors, as well as the interaction test in famSKAT and 
famBT using mean or baseline phenotype data. 
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Table 7 Type I errors for genSKAT and other approaches (α=0.01, positive/negative/no 
effects=80%/0%/20%, 100,000 replicates) 
LD Model 
# of measurements 
2 3 4 
Low genSKAT All 0.0101 0.0101 0.0100 
 famSKAT Baseline 0.0102 0.0102 0.0102 
 Mean 0.0101 0.0100 0.0101 
 famBT Baseline 0.0099 0.0099 0.0099 
 Mean 0.0100 0.0099 0.0100 
Moderate genSKAT All 0.0100 0.0100 0.0101 
 famSKAT Baseline 0.0101 0.0101 0.0101 
 Mean 0.0102 0.0101 0.0101 
 famBT Baseline 0.0098 0.0098 0.0098 
 Mean 0.0098 0.0099 0.0098 
High genSKAT All 0.0100 0.0100 0.0100 
 famSKAT Baseline 0.0103 0.0103 0.0103 
 Mean 0.0101 0.0102 0.0102 
 famBT Baseline 0.0100 0.0100 0.0100 
 Mean 0.0100 0.0101 0.0100 
 
Table 8 Type I errors for genSKAT and other approaches (α=0.001, positive/negative/no 
effects=80%/0%/20%, 100,000 replicates) 
LD Model 
# of measurements 
2 3 4 
Low genSKAT All 0.0010 0.0010 0.0010 
 famSKAT Baseline 0.0009 0.0009 0.0009 
 Mean 0.0010 0.0010 0.0010 
 famBT Baseline 0.0010 0.0010 0.0010 
 Mean 0.0010 0.0011 0.0010 
Moderate genSKAT All 0.0009 0.0009 0.0009 
 famSKAT Baseline 0.0010 0.0010 0.0010 
 Mean 0.0010 0.0010 0.0010 
 famBT Baseline 0.0011 0.0011 0.0011 
 Mean 0.0010 0.0010 0.0010 
High genSKAT All 0.0010 0.0010 0.0010 
 famSKAT Baseline 0.0010 0.0010 0.0010 
 Mean 0.0010 0.0010 0.0010 
 famBT Baseline 0.0010 0.0010 0.0010 
 Mean 0.0010 0.0010 0.0011 
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Table 9 Type I errors for genSKAT and other approaches (α=0.01, positive/negative/no 
effects=40%/40%/20%, 100,000 replicates) 
LD Model 
# of measurements 
2 3 4 
Low genSKAT All 0.0103 0.0102 0.0102 
 famSKAT Baseline 0.0103 0.0103 0.0103 
 Mean 0.0103 0.0102 0.0103 
 famBT Baseline 0.0104 0.0104 0.0104 
 Mean 0.0103 0.0103 0.0104 
Moderate genSKAT All 0.0101 0.0100 0.0102 
 famSKAT Baseline 0.0102 0.0102 0.0102 
 Mean 0.0102 0.0102 0.0101 
 famBT Baseline 0.0104 0.0104 0.0104 
 Mean 0.0103 0.0105 0.0104 
High genSKAT All 0.0100 0.0101 0.0100 
 famSKAT Baseline 0.0102 0.0102 0.0102 
 Mean 0.0101 0.0100 0.0100 
 famBT Baseline 0.0099 0.0099 0.0099 
 Mean 0.0100 0.0103 0.0100 
Table 10 Type I errors for genSKAT and other approaches (α=0.001, positive/negative/no 
effects=40%/40%/20%, 100,000 replicates) 
LD Model 
# of measurements 
2 3 4 
Low genSKAT All 0.0010 0.0010 0.0010 
 famSKAT Baseline 0.0009 0.0009 0.0009 
 Mean 0.0010 0.0009 0.0010 
 famBT Baseline 0.0010 0.0010 0.0010 
 Mean 0.0010 0.0011 0.0011 
Moderate genSKAT All 0.0010 0.0009 0.0010 
 famSKAT Baseline 0.0009 0.0009 0.0009 
 Mean 0.0010 0.0010 0.0010 
 famBT Baseline 0.0009 0.0009 0.0009 
 Mean 0.0010 0.0010 0.0010 
High genSKAT All 0.0010 0.0010 0.0010 
 famSKAT Baseline 0.0009 0.0009 0.0009 
 Mean 0.0010 0.0010 0.0009 
 famBT Baseline 0.0010 0.0010 0.0010 
 Mean 0.0010 0.0010 0.0011 
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3.3.2 Power 
3.3.2.1 Simulation Design 
To evaluate the power of genSKAT for interaction effects and compare it with other 
models, we performed simulation studies. When assume the genetic main effects are 
random effects, the test statistic and its distribution are in the same form as the scenario 
assuming fixed genetic main effects. In our simulations we treated the genetic main 
effects as fixed effects and assumed the outcomes were repeated measurements of the 
same trait. We compared the power of genSKAT, famSKAT and famBT for interaction 
effects. For genSKAT, we included all individuals with all data points. For famSKAT 
and famBT, we used the average of phenotype measurements as the outcome.  
 
When simulating genotype, we set the LD between adjacent variants to be moderate 
because rare variants are rarely in high LD, and generated 100 genotype datasets in the 
same way as for the type I error simulation in section 3.3.1.1. When simulating 
phenotype, we still considered three scenarios: each individual had 2, 3, or 4 phenotype 
measurements. For each scenario, 1,000 phenotype datasets were simulated under two 
designs. 
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(1) To evaluate the interaction between genotype and a continuous covariate, we generate 
the phenotype using 
𝒚 = 0.5𝒙1 + 0.5𝒙2 + 𝑮𝜸 + 𝒙1𝑮𝜼 + 𝜹 + 𝝐. 
 (2) To evaluate the interaction between genotype and a dichotomous covariate, we 
generate the phenotype using  
𝒚 = 0.5𝒙1 + 0.5𝒙2 + 𝑮𝜸 + (𝒙2 − 𝟎. 𝟓)𝑮𝜼 + 𝜹 + 𝝐. 
In these two scenarios, 𝒙1, 𝒙2, 𝜹, and 𝝐 were generated in the same way as in the type I 
error simulation. The vector 𝜸 contains the main effects of causal rare variants. For 𝜸, we 
randomly selected 80% of the rare variants as causal variants, and randomly assigned 
negative effect size to 0% or 50% of the causal variants. The absolute value of main 
effect size 𝛾𝑖 was defined in the same way as in type I error simulations. The vector 𝜼 
contains the interaction effects of causal rare variants. For 𝜼, we randomly assigned 
negative interaction effect sizes to 0% or 50% of the causal variants. The absolute value 
of interaction effect size 𝜂𝑙 for 𝑙
𝑡ℎ variant is defined as 
|𝜂𝑙| = √
𝑐/𝒗′𝑫𝒗
2𝑀𝐴𝐹𝑙(1−𝑀𝐴𝐹𝑙)𝑉𝑎𝑟(𝑥𝑘)
, 𝑘 = 1 or 2.  
We used the same definitions of 𝑐, 𝒗 and 𝑫 as in section 2.3.2.1. The power was equal to 
the proportion of p-values less than or equal to 10−10 in the 100,000 datasets (100 
genotype datasets ×1,000 phenotype datasets). 
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3.3.2.2 Simulation Results 
Figure 2 shows the power simulation results of testing the interaction between genotype 
and a continuous covariate 𝒙1, when the number of repeated measurement per individual 
increases from 2 to 3 to 4. When all interaction effects are in the same direction, famBT 
for interaction effects is more powerful than famSKAT and genSKAT. When half of the 
interaction effects are negative, famBT for interaction effects has almost no power. 
FamSKAT and genSKAT for interaction effects do not dramatically lose power when 
there are opposite direction of interaction effects. With the number of repeated phenotype 
measurements increasing from 2 to 3 to 4, all three approaches gain power. FamSKAT 
and genSKAT have similar power in our simulations. Figure 3 shows the power 
simulation results of testing the gene by binary covariate 𝒙2 interaction. The result in 
Figure 3 is similar to Figure 2. These methods have similar performance when analyzing 
gene by continuous variable interaction and gene by binary variable interaction. From 
both figures, we can observe that power depends on the proportion of negative interaction 
effects instead of the proportion of negative main effects. 
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Figure 2 Power for gene by continuous variable interaction effect tests 
 
The genetic main effects are all positive. The “+/-/0” above each plot represents the 
proportion of positive/negative/null interaction effects. 
  
The genetic main effects are half positive and half negative. The “+/-/0” above each plot 
represents the proportion of positive/negative/null interaction effects. 
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Figure 3 Power for the gene by binary variable interaction effect tests 
 
The genetic main effects are all positive. The “+/-/0” above each plot represents the 
proportion of positive/negative/null interaction effects. 
 
The genetic main effects are half positive and half negative. The “+/-/0” above each plot 
represents the proportion of positive/negative/null interaction effects. 
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3.4 Application to Framingham Heart Study Data 
To show that genSKAT for interaction effects can handle missing values and complex 
family structure in real data, we illustrated our approach by applying genSKAT to 
evaluate the associations between FEV1/FVC and two interaction effects: gene by pack-
years (continuous) interaction and gene by gender (binary) interaction. These two 
covariates are known to be associated with the pulmonary functions. We compared the p-
values of genSKAT, famSKAT and famBT. 
 
For ADAM19 and HTR4, we used the genotype data from Framingham Cohorts for 
Heart and Aging Research in Genomic Epidemiology Targeted Sequencing Project 
(CHARGE-S). Genes previously shown to be related to selected phenotypes were chosen 
for deep re-sequencing as part of the CHARGE-S project. Common variants rs2277027 
and rs1422795 in ADAM19, and rs11168048 and rs7735184 in HTR4 have been reported 
to be related to lung function measurements in a previous genome-wide association study 
[37]. We analyzed polymorphic rare variants with MAF less than 5% only. For 
ADAM19, we included rare variants within ±1kb of the reported common variants 
rs2277027 (region 1) and rs1422795 (region 2). For HTR4, we included rare variants 
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within ±6kb of rs11168048 (region 3) and ±7kb of rs7735184 (region 4). We set different 
gene region lengths in order to include at least 3 rare variants in each region. 
 
We used phenotypes and covariates from Framingham Heart Study offspring cohort at 
exams 5 and 6, and the third generation cohort at exams 1 and 2. We performed the 
genSKAT interaction effects model on all data points. FamSKAT and famBT interaction 
effects were applied to the baseline data. Similar to a previous longitudinal CHARGE-S 
study on FEV1/FVC [57], we adjusted the analyses for age, sex, height, smoking status, 
pack-years, and principal components.  
 
Table 11 and Table 12 show the p-values of the association tests for each region. We 
compare the p-values to an adjusted significance threshold for multiple tests by 
Bonferroni correction, which is 0.05/4=0.0125. None of the tests reach statistical 
significance in regions 1, 3, and 4. There may be no interactions, or we do not have 
enough power to detect interaction effects. GenSKAT for the gene by sex interaction at 
region 2 reaches the Bonferroni adjusted significance level. It is not captured by 
famSKAT or famBT. This association could be true or a false positive. Further 
investigation is needed. This application shows that genSKAT can handle missing values 
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in real data. The participants in this Framingham Heart Study data also have more 
complex familial correlations than the nuclear families in our simulation studies.  
 
Table 11 Application of genSKAT for interaction effects to gene by pack-years 
Gene Region 
# of 
persons 
# of 
variants 
p-values 
genSKAT famSKAT famBT 
ADAM19 
Region 1 1104 11 0.0481 0.4955 0.0630 
Region 2 1104 9 0.0196 0.8015 0.3076 
HTR4 
Region 3 1104 13 0.0576 0.2688 0.1090 
Region 4 1104 2 0.5857 0.5901 0.5980 
Region 1: rs2277027±1kb; region 2: rs1422795±1kb; region 3: rs11168048±6kb; region 
4: rs7735184±7kb. For genSKAT, 𝑁𝑜𝑏𝑠 =1927. 
Table 12 Application of famSKAT and famBT for interaction effects to gene by sex 
Gene Region 
# of 
persons 
# of 
variants 
p-values 
genSKAT famSKAT famBT 
ADAM19 
Region 1 1104 11 0.1591 0.9995 0.7850 
Region 2 1104 9 0.0118 0.1967 0.2068 
HTR4 
Region 3 1104 13 0.3964 0.9999 0.9557 
Region 4 1104 2 0.8107 0.7285 0.5329 
Region 1: rs2277027±1kb; region 2: rs1422795±1kb; region 3: rs11168048±6kb; region 
4: rs7735184±7kb. For genSKAT, 𝑁𝑜𝑏𝑠 =1927. 
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3.5 Discussion 
In our research, we discussed a gene-environment interaction test in the genSKAT 
framework. GenSKAT for G-E interaction effects is equivalent to the G-E interaction test 
in famSKAT when only 1 observation per individual, and equivalent to the G-E 
interaction test in SKAT if there is also no correlation between individuals.  
 
We showed that genSKAT for interaction effects has the correct type I error for family 
data with repeated quantitative measurements or multiple quantitative traits in the 
scenarios evaluated. GenSKAT and famSKAT for interaction effects have comparable 
power in our simulations. FamBT for interaction effects is more powerful when 
interaction effects in the same direction and less powerful when the interaction effects in 
opposite direction. In real data, when information about the true direction of the G-E 
interaction effects is not available, we recommend the use of famSKAT or genSKAT 
instead of burden tests. In addition, the power of genSKAT, famSKAT and famBT for 
interaction effects does not depend on the proportion of negative main effects. 
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We applied genSKAT to 4 gene regions that contain common variants previously shown 
to be associated with FEV1/FVC in large GWAS [37]. We evaluated the interactions 
between the rare variants in these genes and two covariates, pack-years and gender. 
These two covariates are known to be associated pulmonary traits. Pack-years measures 
lifetime smoking, which is continuous. Gender is a binary variable. We noted that the 
sample size in Framingham Heart Study alone, even with the repeated measurements, 
was relatively small to detect gene by environment interactions. We did not find any 
significant gene by pack-years interaction effects in all 4 regions, or any gene by sex 
interaction effects in region 1, 3, and 4. GenSKAT provides a borderline significant p-
value for gene by sex interaction at region 2. It is not captured by famSKAT or famBT. 
This association could be true or a false positive. Further investigation is needed. In our 
sample, some individuals had missing phenotype or covariates measurements. Our 
sample also has a complex family structure. This application shows that genSKAT for 
interaction effects is a general and flexible approach that can be applied to complex real 
data.  
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Chapter 4 Gene-based Meta-analysis for Cohorts with Different Designs 
4.1 Introduction 
For rare variants, large sample sizes are needed to have adequate power to detect 
associations [31]. However, sequencing studies to assess the association with rare 
variants often only have hundreds of participants, and thus may not be well powered. 
Because of the high cost of sequencing, privacy issues, and the rareness of some traits or 
diseases, it is may be difficult to recruit more participants within a study. Multiple studies 
with the same traits available may be combined to increase power. Meta-analysis is often 
used to combine results from multiple studies to increase sample size and power. It has 
some advantages over joint analysis of pooled data from all studies. First, only cohort-
specific summary statistics are required for meta-analysis and individual level data are 
not needed. This approach avoids some ethical concerns with sharing of human genetics 
data. Also it is much easier to share summary statistic files because of the smaller file 
sizes compared to individual-level datasets. Second, meta-analysis allows studies to use a 
different set of covariates. It is usually difficult to perform joint analysis if different 
studies use different covariates. Also studies may have different study designs. For 
example, we can meta-analyze family studies with studies of unrelated individuals. 
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Different meta-analysis approaches depend on which assumption is made regarding the 
effect estimates across studies. Under the assumption of homogeneity of effect sizes, 
effect sizes are expected to be the same in all participating studies and only differ from 
each other due to sampling variation. If studies come from separate populations or have 
diverse environmental factors such as dietary or lifestyle behaviors, then genetic effect 
sizes may differ across studies, causing heterogeneity of effect sizes. In meta-analysis for 
rare variants, heterogeneity between studies may also be introduced by the different 
sequencing technologies and quality control processes.  
 
In the context of rare variants, one meta-analysis strategy is to combine test statistics 
instead of regression coefficients, because the regression coefficients may have large 
variances due to the low allele frequency of the rare variants [32]. Lee et al. proposed a 
general framework for rare variants meta-analysis [32] for commonly used rare variant 
analysis methods, such as burden tests, SKAT, famSKAT, and SKAT-O. This approach 
uses the minor allele frequency and score statistics for each rare variant, and the 
covariance matrix of the score statistics from each study. The rare variant meta-analysis 
approach propose by Lee et al. is computationally efficient, because p-values can be 
calculated analytically.  
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GenSKAT is an extension of SKAT and famSKAT. The genSKAT test statistic has 
similar structure and distribution as the SKAT and famSKAT statistics. Extension of the 
meta-analysis framework to accommodate genSKAT is feasible. In meta-analyses, 
different studies may have different study designs. Some studies may consist of unrelated 
individuals, while others may have family samples, and both types of studies may also 
include longitudinal data or repeated measurements. The genSKAT approach we 
proposed in chapter 2 is a flexible method that can be applied to all these types of study 
designs.  
 
In this chapter, we discuss meta-analyses of genetic main effects. We evaluate genSKAT 
meta-analyses with simulations to examine type I error for different combinations of 
study designs. We note that there is no previous research evaluating type I error of 
famSKAT meta-analysis. So we also estimate the type I error in our simulations for 
famSKAT using baseline data when repeated measures are available. 
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We perform simulation studies to evaluate the power of genSKAT meta-analysis when 
sample sizes and effect sizes may differ between studies. We compare the power of 
genSKAT meta-analysis assuming homogeneous genetic effects, genSKAT meta-analysis 
assuming heterogeneous genetic effects, genSKAT joint analysis on pooled data 
combining all individuals, and famSKAT meta-analysis using baseline measurements 
assuming heterogeneity under different scenarios.  
 
4.2 Method 
We assume that there are 𝐾 studies to be meta-analyzed. For the 𝑘𝑡ℎ study, where 𝑘 =
1,2, … , 𝐾, we consider the same linear mixed effects model as for genSKAT, 
𝒚𝑘 = 𝑿𝑘𝜷𝑘 + 𝑮𝑘𝜸𝑘 + 𝜹𝑘 + 𝝐𝑘, 
𝜸𝑘 ~ 𝑁(𝟎, 𝜏𝑘𝑾𝑘), 
𝜹𝑘~𝑁(𝟎,𝚽𝑘⊗𝑨𝑘), 
𝝐𝑘~𝑁(𝟎, 𝑰𝑛⊗𝑹
𝑘),   
where 𝒚𝑘, 𝑿𝑘 , 𝜷𝑘, 𝑮𝑘, 𝜏𝑘 ,𝑾𝑘, 𝚽𝑘 , 𝑨𝑘and 𝑹𝑘 are defined in the same way as 𝒚, 𝑿, 𝜷, 𝑮, 𝜏, 
𝑾,𝚽,𝑨, and 𝑹 in section 2.2, but with a superscript 𝑘 indicating the study number. 
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Participating studies may have different sets of covariates, different numbers of repeated 
measurements, and various family structures. So parameters 𝒚𝑘, 𝑿𝑘, 𝜷𝑘, 𝑮𝑘 ,𝑾𝑘, 
𝚽𝑘, 𝑨𝑘and 𝑹𝑘 may have different dimensions in different studies. 
 
4.2.1 Study Level Statistics 
The genSKAT test statistic for testing the null hypothesis 
𝐻0: 𝜸
𝑘 = 𝟎 𝑣𝑠.  𝐻1: 𝜸
𝑘 ≠ 𝟎,   
or equivalently in our model settings, 
𝐻0: 𝜏
𝑘 = 0 𝑣𝑠.  𝐻1:  𝜏
𝑘 ≠ 0. 
can be written as 
𝑄𝑘 = (𝒚𝑘 − 𝑿𝑘?̂?𝑘)
𝑇
?̂?𝑘
−1
𝑮𝑘𝑾𝑘𝑮𝑘
𝑇
?̂?𝑘
−1
(𝒚𝑘 − 𝑿𝑘?̂?𝑘). 
The un-weighted score statistic for study 𝑘 is  
𝑺𝑘 = 𝑮𝑘
𝑇
?̂?𝑘
−1
(𝒚𝑘 − 𝑿𝑘?̂?𝑘), 
where ?̂?𝑘 and ?̂?𝑘 are maximum likelihood estimators of 𝚺𝑘 and 𝜷𝑘,  
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?̂?𝑘 = 𝚽𝑘⊗ ?̂?𝑘 + 𝑰𝑛⊗ ?̂?
𝑘, 
?̂?𝑘 = (𝑿𝑘
𝑇
?̂?𝑘
−1
𝑿𝑘)
−1
𝑿𝑘
𝑇
?̂?𝑘
−1
𝒚𝑘. 
The variance of the un-weighted score statistic 𝑺𝑘 is  
𝑽𝑘 = 𝑮𝑘
𝑇
?̂?𝑘
−1
𝑉𝑎𝑟(𝒚𝑘 − 𝑿𝑘?̂?𝑘)?̂?𝑘
−1
𝑮𝑘  
      = 𝑮𝑘
𝑇
?̂?𝑘
−1
(?̂?𝑘 − 𝑿𝑘𝑉𝑎𝑟(?̂?𝑘)𝑿𝑘
𝑇
)?̂?𝑘
−1
𝑮𝑘 
      = 𝑮𝑘
𝑇
?̂?𝑘
−1
(?̂?𝑘 − 𝑿𝑘 (𝑿𝑘
𝑇
?̂?𝑘
−1
𝑿𝑘)
−1
𝑿𝑘
𝑇
) ?̂?𝑘
−1
𝑮𝑘 
      = 𝑮𝑘
𝑇
(?̂?𝑘
−1
− ?̂?𝑘
−1
𝑿𝑘 (𝑿𝑘
𝑇
?̂?𝑘
−1
𝑿𝑘)
−1
𝑿𝑘
𝑇
?̂?𝑘
−1
)𝑮𝑘. 
In each study, we record 𝑺𝑘, 𝑽𝑘 and the minor allele frequency of each rare variable. 
These quantities will be used for meta-analysis. We discuss two types of meta-analysis, 
one approach when genetic main effects are assumed to be homogeneous across studies, 
and another approach when genetic main effects are assumed to be heterogeneous across 
studies. 
 
69 
 
 
4.2.2 Meta-analysis Assuming Homogeneity 
First we discuss meta-analysis tests assuming that the effect sizes of genetic variants are 
the same across studies. To perform a meta-analysis under the homogeneity assumption, 
we combine the score statistics as Lee et al. proposed [32]: 
𝑄ℎ𝑜𝑚 =∑(∑𝑤𝑖
𝑘𝑆𝑖
𝑘
𝐾
𝑘=1
)
2𝑞
𝑖=1
. 
 
Because of the homogeneity assumption, we usually use the same weight across studies 
for each rare variant based on its average minor allele frequency or prior information. 
That is, 𝑤𝑖
𝑘 = 𝑤𝑖 for 𝑘 = 1,2, … , 𝐾. For example, if we use the Wu weights for rare 
variants, 𝑤𝑖 = 𝐵𝑒𝑡𝑎(𝑀𝐴𝐹𝑖, 1,25), the 𝑀𝐴𝐹𝑖 will be the average minor allele frequency 
across all studies. When using the same weights for all studies, we can rewrite the 𝑄ℎ𝑜𝑚 
in matrix form, as described below. 
 
Within each gene region, we sum up the weighted score vectors and un-weighted 
covariance matrices across all studies 
𝑺ℎ𝑜𝑚 = √𝑾∑𝑺
𝑘
𝐾
𝑘=1
,   𝑽ℎ𝑜𝑚 =∑𝑽
𝑘
𝐾
𝑘=1
, 
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where 𝑾 = 𝑑𝑖𝑎𝑔(𝑤1
2, 𝑤2
2, … , 𝑤𝑞
𝟐) is a diagonal weight matrix for 𝑞 rare variants. Then  
𝑄ℎ𝑜𝑚 = 𝑺ℎ𝑜𝑚
𝑇 𝑺ℎ𝑜𝑚. 
Using the same argument we used to estimate the distribution of genSKAT statistic, we 
find that under the null hypothesis,  
𝑄ℎ𝑜𝑚 ∼∑𝜆ℎ𝑜𝑚,𝑗𝜒1,𝑗
2
𝑞
𝑗=1
 , 
where 𝜆ℎ𝑜𝑚,𝑗 are the eigenvalues of √𝑾𝑽ℎ𝑜𝑚√𝑾, and 𝜒1,𝑗
2  are independent 𝜒1
2 random 
variables. The p-value can be computed using the Davies method [10] from the R 
package CompQuadForm [12] or the Kuonen’s saddlepoint method [30] from the R 
package survey [39]. The Davies’ method is slightly faster than the saddlepoint 
approximation. Chen et al. recommended the use of the Kuonen’s saddlepoint method 
when p-values are expected to be very small because the Davies’ method is less accurate 
for small p-values [8]. 
 
4.2.3 Meta-analysis Assuming Heterogeneity                                                               
Genetic main effects may be heterogeneous across studies. To derive a meta-analysis 
statistic that allows for heterogeneity, we assume that the effect sizes of rare variants in 
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different studies are independent and follow the same distribution. The meta-analysis 
statistic is given by [32] 
𝑄ℎ𝑒𝑡 =∑∑𝑤𝑖
𝑘2𝑆𝑖
𝑘2
𝐾
𝑘=1
𝑞
𝑖=1
, 
where 𝑤𝑖
𝑘 is the study-specific weight for 𝑖𝑡ℎ variant in 𝑘𝑡ℎ study, and 𝑆𝑖
𝑘 is the study-
level score for 𝑖𝑡ℎ variant in 𝑘𝑡ℎ study.  
 
We can re-write 𝑄ℎ𝑒𝑡 in a matrix form as described below. The cumulative score vector 
for 𝑞 variants can be given by  
𝑺ℎ𝑒𝑡 = √𝑾∗𝑺
∗, 
where 𝑾∗ = 𝑑𝑖𝑎𝑔(𝑾1,𝑾2, … ,𝑾𝐾), and 𝑺∗ = (𝑺1, 𝑺2, … , 𝑺𝐾 )𝑇. Then  
𝑄ℎ𝑒𝑡 = 𝑺ℎ𝑒𝑡
𝑇 𝑺ℎ𝑒𝑡. 
Under the null hypothesis,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
𝑄ℎ𝑒𝑡 ∼∑𝜆ℎ𝑒𝑡,𝑗𝜒1,𝑗
2
𝑞
𝑗=1
 , 
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Where 𝜒1,𝑗
2  are independent 𝜒1
2 random variables, and 𝜆𝑗 are the eigenvalues of 
√𝑾∗𝑽∗√𝑾∗, with 
𝑽∗ = 𝑉𝑎𝑟(𝑺∗) = 𝑑𝑖𝑎𝑔(𝑽1, 𝑽2, … , 𝑽𝐾). 
The p-value can be computed using the Davies method [10] from the R package 
CompQuadForm [12] or the Kuonen’s saddlepoint method [30] from the R package 
survey [39].  
 
Sometime, studies may belong to subgroups according to prior information. For example, 
a meta-analysis project may group studies by their geographic locations and ancestries. In 
each subgroup, the assumption of homogeneity may hold. In this case, we can first apply 
a meta-analysis test assuming homogeneity within each subgroup and then perform meta-
analysis assuming heterogeneity across subgroups. 
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4.3 Simulation Studies 
4.3.1 Type I Error 
4.3.1.1 Simulation Design 
We performed simulations to estimate the type I error of genSKAT meta-analyses 
statistic assuming either homogeneity or heterogeneity in genetic main effects. We 
noticed that there was no previous research evaluating the type I error of famSKAT meta-
analysis. Therefore, we also estimated the type I error for famSKAT meta-analysis using 
the baseline measurements in our simulations.  
 
We considered 4 different study designs: A, B, C and D (Table 13). The samples of study 
designs A and C consisted of unrelated individuals, and the samples of study designs B 
and D consisted of nuclear families with two parents and two offspring. Additionally, 
each individual in study designs A and B had only 1 measurement, while each individual 
in study designs C and D had 3 measurements. GenSKAT can be directly applied to these 
4 study designs. FamSKAT can be directly performed on study designs A and B, but only 
baseline or average outcome measurements can be used in the case of study designs C or 
D. 
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Table 13 Different study designs 
Study Design Number of Repeated Measurements Family size 
A 1 1 
B 1 4 
C 3 1 
D 3 4 
 
We considered two different scenarios for the sample size in each study. The first 
scenario consists of all studies having the same number of individuals. In our simulations, 
we set the number of individuals to be 1,000 for each study. This means that the numbers 
of observations for study designs A and B are both 1,000, and the numbers of 
observations for study designs C and D are both 3,000. The second scenario consists of 
all studies having the same number of observations. In our simulations, we controlled the 
total number of observations to be 3,000 for all 4 study designs. This means 3,000 
unrelated individuals for study design A, and 750 nuclear families with 2 parents and 2 
offspring for study design B. For each scenario of the sample size, we evaluated the type 
I errors in three scenarios: meta-analyzing 4 type D studies, meta-analyzing 10 type D 
studies, and meta-analyzing 4 studies, one from each of type A, B, C and D respectively. 
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We generated 1,000 genotype datasets for each study. For studies with family samples, 
the genotype simulations were similar as in section 2.3.1.1. We assumed 18 variants with 
minor allele frequencies from 0.002 to 0.05. We first generated latent variables from the 
multivariate normal distribution with a first order autoregressive covariance structure. 
Then the latent variables were dichotomized at specific quantiles decided by the minor 
allele frequencies to generate the haplotypes for founders. The haplotypes were passed 
down to offspring without recombination according to Mendel’s segregation law. For 
studies with unrelated individuals, we followed the same genotype simulation process but 
stopped after generating haplotypes for founders.   
 
For each genotype dataset, we generated 1,000 phenotype datasets. We simulated the 
continuous phenotype using the formula 
𝒚𝑘 = 0.5𝒙1
𝑘 + 0.5𝒙2
𝑘 + 𝜹𝑘 + 𝝐𝑘,   
where 𝒙1
𝑘~𝑁(𝟎, 𝟏) and 𝒙2
𝑘~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(0.5), and 𝜹𝑘and 𝝐𝑘 are generated from 
multivariate normal distribution 𝑁(𝟎,𝚽𝑘⊗𝑨𝑘) and 𝑁(𝟎, 𝑰𝑛⊗𝑹
𝑘) respectively. The 
matrix 𝚽𝑘 is the relationship coefficient matrix for study designs B and D, and the 
identity matrix for study designs A and C. 𝑨𝑘 and 𝑹𝑘 were defined by 
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𝑨𝑘 = {
(
1.60 0.96 0.96
0.96 1.60 0.96
0.96 0.96 1.60
) , for study design C or D
1.60, for study design A or B
 , 
𝑹𝑘 = {
(
2.40 1.20 0.96
1.20 2.40 1.20
0.96 1.20 2.40
) , for study design C or D
2.40, for study design A or B
 . 
These definitions followed the same rationale as in section 2.3.1.1. There are no genetic 
effects in this model because we are evaluating type I error simulation under null 
hypothesis. 
 
When evaluating p-values, we used Wu weights for both genSKAT meta-analyses 
assuming homogeneity and assuming heterogeneity, although minor allele frequencies 
(MAFs) used vary depending on the homogeneity or heterogeneity assumption. For meta-
analyses assuming homogeneity, we calculated the Wu weights on average MAFs from 
all studies, and used them as weights for all studies. For meta-analyses assuming 
heterogeneity, we calculated study-specific weights with the study-specific MAFs. The 
empirical type I error was calculated at α levels of 0.01, 0.001 and 0.0001. The type I 
error was equal to the proportion of p-values less than or equal to the corresponding α 
level in the 1 million datasets (1,000 genotype datasets × 1,000 phenotype datasets). 
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4.3.1.2 Simulation Results 
The type I error simulation results for genSKAT meta-analysis assuming homogeneity or 
heterogeneity and other methods are displayed in Table 15 to Table 17. All repeated 
measurements were included in genSKAT meta-analyses. Only the baseline measure was 
used in famSKAT meta-analyses. We evaluated type I errors for 6 scenarios with 
different sample sizes and different study designs. Table 14 shows the number of 
observations and number of individuals in each study for the 6 scenarios. As seen in 
Table 15 to Table 17, the type I error of all methods is well controlled for all significance 
levels evaluated.   
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Table 14 Study designs for type I error simulations 
Sample size scenario Study design Ninviduals Nobservations 
Same number of  
individuals 
4 × D 1,000 for each study 3,000 for each study 
10 × D 1,000 for each study 3,000 for each study 
A, B, C, D 1,000 for each study 1,000, 1,000, 3,000, 3,000 
Same number of  
observations 
4 × D 1,000 for each study 3,000 for each study 
10 × D 1,000 for each study 3,000 for each study 
A, B, C, D 3,000, 3,000, 1,000, 1,000 3,000 for each study 
 
 
Table 15 Type I errors for different meta-analysis approaches (α=0.01) 
Sample size scenario Study design 
Method 
genSKAT 
Hom Meta 
genSKAT 
Het Meta 
famSKAT 
Hom Meta 
famSKAT 
Het Meta 
Same number of  
individuals 
4 × D 0.0097 0.0098 0.0101 0.0102 
10 × D 0.0097 0.0099 0.0101 0.0102 
A, B, C, D 0.0099 0.0099 0.0102 0.0103 
Same number of  
observations 
4 × D 0.0096 0.0097 0.0101 0.0101 
10 × D 0.0098 0.0010 0.0100 0.0099 
A, B, C, D 0.0010 0.0099 0.0100 0.0101 
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Table 16 Type I errors for different meta-analysis approaches (α=0.001) 
Sample size scenario Study design 
Method 
genSKAT 
Hom Meta 
genSKAT 
Het Meta 
famSKAT 
Hom Meta 
famSKAT 
Het Meta 
Same number of  
individuals 
4 × D 0.0009 0.0009 0.0011 0.0010 
10 × D 0.0010 0.0009 0.0010 0.0010 
A, B, C, D 0.0009 0.0009 0.0010 0.0011 
Same number of  
observations 
4 × D 0.0009 0.0009 0.0010 0.0010 
10 × D 0.0009 0.0010 0.0010 0.0010 
A, B, C, D 0.0010 0.0009 0.0010 0.0010 
 
 
 
Table 17 Type I errors for different meta-analysis approaches (α=0.0001) 
Sample size scenario Study design 
Method 
genSKAT 
Hom Meta 
genSKAT 
Het Meta 
famSKAT 
Hom Meta 
famSKAT 
Het Meta 
Same number of  
individuals 
4 × D 0.00010 0.00009 0.00011 0.00010 
10 × D 0.00010 0.00010 0.00010 0.00010 
A, B, C, D 0.00009 0.00009 0.00010 0.00011 
Same number of  
observations 
4 × D 0.00009 0.00009 0.00011 0.00011 
10 × D 0.00009 0.00010 0.00010 0.00010 
A, B, C, D 0.00010 0.00010 0.00010 0.00010 
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4.3.2 Power 
4.3.2.1 Simulation Design 
We performed simulations to evaluate the power of genSKAT meta-analyses, assuming 
homogeneity or heterogeneity in genetic main effects. We compared the power to 
genSKAT joint analysis on pooled data, and to famSKAT meta-analysis assuming 
heterogeneity. Similar to the type I error simulations, we were interested in 4 different 
study designs, A, B, C and D defined in Table 13. We considered two different scenarios 
of the sample size: all studies with the same number of individuals, and all studies with the 
same number of observations. For each sample size scenario, we evaluated the power of 
meta-analyzing 4 studies, 1 from each study design A, B, C, and D. 
 
We generated 1,000 genotype datasets in the same way described in the type I error 
simulation section. For each of 100,000 iterations, 4 genotype datasets were randomly 
sampled from the 1,000 genotype datasets and were assigned to be the genotypes for 4 
studies of type A, B, C, and D respectively. For each set of 4 genotype datasets, we 
generated the continuous phenotypes using the formula 
𝒚𝑘 = 𝑮𝑘𝜸𝑘 + 𝜹𝑘 + 𝝐𝑘, 𝑘 = 1,2,3,4,  
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where 𝜹𝑘and 𝝐𝑘 were generated from multivariate normal distribution 𝑁(𝟎,𝚽𝑘⊗𝑨𝑘) 
and 𝑁(𝟎, 𝑰𝑛⊗𝑹
𝑘) respectively, and 𝑮𝑘 was the genotype matrix, and 𝜸𝑘 contained the 
random effects of rare variants. 𝚽𝑘 was the relationship coefficient matrix for study 
design B or D, and the identity matrix for study design A or C. 𝑨𝑘 and 𝑹𝑘 were defined 
in the same way as in type I error simulations. We did not include any covariates in the 
model. In meta-analyses on real data, each study may run study-level models adjusting 
for covariates and generate residuals. Then the residuals from each study can be treated 
as the new outcome.  
 
We randomly selected 50% of the rare variants as causal variants, and randomly assigned 
negative effect size to half of the causal variants. The absolute value of effect size 𝛾𝑙 was 
defined similarly as in section 2.3.2.1. We want to evaluate power of the meta-analyses 
methods in three effect size scenarios: 1) all studies have the same effect sizes; 2) studies 
with a single measurement per person (types A and B) have half of the effect sizes of 
studies with repeated measurements (types C and D); and 3) study types C and D have 
half of the effect sizes of study types A and B. When calculating the Wu weights for rare 
variants, we used the average MAFs for meta-analyses assuming homogeneity, and used 
the study-specific MAFs for meta-analyses assuming heterogeneity.  
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4.3.2.2 Simulation Results  
The left panel from Figure 4 shows the power simulation results for genSKAT meta-
analyses and other methods when the number of participants is the same in all 4 studies, 
which means different number of observations for studies with 1 observation per person 
and studies with 3 observations per person. GenSKAT meta-analysis assuming 
homogeneity has similar power as genSKAT joint analysis on pooled data. They both use 
the same average minor allele frequencies to calculate the weights for rare variants. When 
the genetic effect are homogeneous across all studies, which is scenario 1, genSKAT 
meta-analysis assuming homogeneity is more powerful compared to the one assuming 
heterogeneity. FamSKAT meta-analysis has the lowest power because it only includes 
4,000 baseline observations while other methods use 8,000 observations. In scenarios 2 
and 3, the difference effect sizes introduce some heterogeneity. The power of genSKAT 
meta-analysis assuming homogeneity and the power of genSKAT meta-analysis 
assuming heterogeneity are closer. If studies come from different populations, e.g. studies 
share a small proportion of shared causal variants, the minor allele frequencies are 
different, or the LD structure varies, genSKAT meta-analysis assuming homogeneity may 
lose more power and be out-performed by genSKAT meta-analysis assuming 
heterogeneity. The power of famSKAT meta-analysis assuming heterogeneity is similar 
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in scenarios 2 and 3, because the effect size changes happen to the same number of 
individuals used by this method.  
 
The right panel from Figure 4 shows the power simulation results for genSKAT meta-
analyses and other methods when the number of observations is the same for all 4 studies, 
arising from different number of individuals for studies with 1 observation per person and 
studies with 3 observations per person. As in the left panel of Figure 4, genSKAT meta-
analysis assuming homogeneity and the joint genSKAT analysis have similar power. 
They out-perform genSKAT meta-analysis assuming heterogeneity in scenario 1. In 
scenario 2 and 3, the different effect sizes introduce some heterogeneity. The power 
difference between genSKAT meta-analyses assuming homogeneity and assuming 
heterogeneity are decreased. FamSKAT meta-analysis has the lowest power among all 
methods since it only uses part of the data. The power of famSKAT meta-analysis 
increases from scenario 2 to scenario 3, because fewer individuals have smaller effect 
sizes in the latter scenario. 
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Figure 4 Power comparison for genSKAT meta-analysis and other approaches 
 
Left: same number of individuals in all studies; right: same number of observations in all 
studies. Scenario 1: all studies have the same effect sizes; scenario 2: studies with a single 
measurement per person have half of the effect sizes of studies with repeated 
measurements; scenario 3: studies with repeated measurements have half of the effect 
sizes of studies with a single measurement per person.  
  
85 
 
 
4.4 Discussion 
We discussed gene-based meta-analysis for the genSKAT statistic. In meta-analyses, 
different studies may have different study designs. Some designs consist of only 
unrelated participants, other designs include family samples, with or without longitudinal 
data or repeated measurements. Ignoring the correlation structure in related individuals or 
multiple measures from the same person may result in elevated type-I error.  Omitting 
correlated observations may lead to power loss. Because genSKAT is a flexible method 
that can adjust for the correlations between rare variants, family members, and repeated 
measurements, it can be applied to various study designs. In this chapter, we showed how 
to meta-analyze results from genSKAT assuming homogeneity or heterogeneity of 
genetic effects. 
 
In our simulations, we introduced 4 study designs: family studies with or without 
repeated measurements, and studies of unrelated individuals with or without repeated 
measurements. We showed that genSKAT and famSKAT meta-analyses assuming 
homogeneity or heterogeneity have the correct type I error under various situations: 4 
family studies with repeated measurements, 10 family studies with repeated 
measurements, and 4 studies with 1 from each of 4 study designs. 
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We performed simulation studies to evaluate power when sample sizes and effect sizes 
varied across studies. We simulated 6 different scenarios with different sample sizes and 
genetic effect sizes. When all studies shared the same effect sizes, genSKAT meta-
analysis assuming homogeneity and genSKAT joint analysis on pooled individual level 
data had similar power in the scenarios evaluated. This is because the test statistics for 
both approaches are the same when using the same weights for rare variants when there 
are no covariates in the model. GenSKAT meta-analysis assuming homogeneity out-
performed genSKAT meta-analysis assuming heterogeneity when there is no 
heterogeneity present. When some heterogeneity is introduced by the differences in 
genetic effect sizes, the power of genSKAT meta-analysis assuming homogeneity and the 
power of genSKAT assuming heterogeneity are closer. Because genSKAT meta-analyses 
take advantage of the full data, they are more powerful than famSKAT meta-analyses on 
baseline data in our simulations. 
 
The genSKAT meta-analysis approach only requires genSKAT score statistic and minor 
allele frequency for each variant, and a covariance matrix of the scores from each study. 
GenSKAT meta-analysis is not based on regression coefficients because the estimated 
regression coefficients are usually unstable due to the low allele frequency of rare 
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variants. Meta-analysis does not require individual level data, thus avoiding the ethical 
concerns with sharing human genetic data. It also reduces the resources needed to transfer 
large amount of genetic data between analysts. More importantly, meta-analysis allows 
different studies to adjust for different variables.   
  
With faster and cheaper genotype sequencing technologies, more genetic data will be 
available from existing and new studies, some with longitudinal measurements available. 
Meta-analysis of genSKAT results is an efficient way to increase the power to detect 
novel rare variant associations.  
 
Although we performed simulations assuming repeated phenotype measurements, 
genSKAT can also be applied to meta-analyze multiple traits when such data are 
available. Lee et al have shown that Hom-Meta-SKAT-O and Het-Meta-SKAT-O are 
more powerful than Hom-Meta-SKAT and Het-Meta-SKAT respectively [32]. Replacing 
SKAT meta-analysis statistic by genSKAT meta-analysis statistic in Hom-Meta-SKAT-O 
and Het-Meta-SKAT-O, we can easily obtain genSKAT-O meta-analysis to further 
improve power.  
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Chapter 5 Future Work and Summary 
5.1 Summary 
Genetic loci identified to date by single variant association tests only account for a small 
proportion of the heritability for most complex traits and diseases. The unexplained 
heritability may be due to rare variants or gene by environment interaction. In chapter 2, 
we proposed a general SKAT framework to perform gene-based main effect test on 
family samples with multiple measurements per person. This approach is also useful to 
jointly analyze multiple traits, thereby improving our understanding of complex diseases. 
GenSKAT is an extension of SKAT and famSKAT that adjusts for the correlations 
between rare variants, between individuals, and between multiple measurements within a 
person. In chapter 3, we further discussed genSKAT for gene by environment interaction 
effects. Even though there are several statistical models designed for rare variant 
association studies, it is still difficult to find rare variant associations in real datasets. One 
reason is the relatively small sample size of each study. Meta-analysis is a popular 
approach to increase the power by combining multiple studies with the same outcome. In 
chapter 4, we discussed a meta-analysis framework for genSKAT results. Various 
simulations were performed to show that the type I error is well controlled in different 
scenarios. Using a different set of simulations, we also evaluated the power of genSKAT 
meta-analyses assuming homogeneous or heterogeneous genetic main effects across 
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studies, genSKAT joint meta-analysis, and famSKAT meta-analysis assuming 
heterogeneous genetic main effects under various sample sizes and effect sizes. 
Combining all these projects together, we contribute methodologies to detect rare variants 
associations by taking advantage of more information.  
 
5.2 Discussion and Future Work 
In chapter 2, we developed genSKAT for continuous outcomes. For categorical 
outcomes, the covariance structure due to familial correlation needs to be incorporated in 
other ways than through a kinship matrix. This is a typical limitation of genSKAT and 
famSKAT. The original SKAT can be applied to both continuous and categorical 
outcomes because it does not require adjustment for family structure. Future work on 
exploring ways to define the covariance matrix or finding a transformation of the 
outcome is needed.  
 
We performed simulations assuming the phenotype is repeated measurements. Further 
simulations for jointly analyzing multiple traits is needed. Two additional covariance 
matrices are introduced into the genSKAT model for correlations between multiple 
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measurements, which means more parameters are estimated and hence a larger sample is 
needed. For repeated measurements, we may assume specific covariance structure based 
on prior information of the outcome to reduce the number of parameters. For multiple 
traits, it is usually hard to pre-specify the covariance structure. If we set the covariance to 
be unstructured, there are 𝑚(𝑚 + 1) parameters to be estimated for these two matrices. 
For 1 more trait, we need to additionally estimate 2(𝑚 + 1) parameters. If the sample 
size is small, we may see unstable estimates of the parameters. Further work on how the 
number of traits affects type I error and power is needed. It is also worthy to explore 
other ways of using fewer parameters to incorporate the correlation of multiple 
measurements in the models. Additionally, we may investigate the model performance 
using different types of covariance structures, e.g. time-dependent genetic covariance 
between multiple measurements. 
 
In the process of creating genSKAT statistic, we need to perform matrix multiplication 
and calculate inverses of multiple matrices, inducing computational intensity for large 
samples with a high number of repeated measurements per person. Further work on 
improving computational efficiency is needed. 
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In chapter 3, we discussed genSKAT to test for the presence of gene by environment 
interaction effects. Chen et al. have proposed a joint test of both main effect and G-E 
interaction effect under the SKAT framework [7].We may be able to use similar ideas to 
develop a joint test in the genSKAT framework.  
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